10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

Or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to                     

Commission file number 1-11239

HCA Healthcare, Inc.

(Exact name of registrant as specified in its charter)

Delaware	27-3865930
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
One Park Plaza Nashville, Tennessee	37203
(Address of principal executive offices)	(Zip Code)

(615) 344-9551

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐  (Do not check if a smaller reporting company)	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

Class of Common Stock	Outstanding at July 31, 2017
Voting common stock, $.01 par value	361,249,700 shares

HCA HEALTHCARE, INC.

Form 10-Q

June 30, 2017

		Page of Form 10-Q
Part I.	Financial Information
Item 1.	Financial Statements (Unaudited):
	Condensed Consolidated Income Statements — for the quarters and six months ended June 30, 2017 and 2016		2
	Condensed Consolidated Comprehensive Income Statements — for the quarters and six months ended June 30, 2017 and 2016		3
	Condensed Consolidated Balance Sheets — June 30, 2017 and December 31, 2016		4
	Condensed Consolidated Statements of Cash Flows — for the six months ended June 30, 2017 and 2016		5
	Notes to Condensed Consolidated Financial Statements		6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		44
Item 4.	Controls and Procedures		44
Part II.	Other Information
Item 1.	Legal Proceedings		44
Item 1A.	Risk Factors		44
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		45
Item 6.	Exhibits		46
Signatures			47

1

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED INCOME STATEMENTS

FOR THE QUARTERS AND SIX MONTHS ENDED JUNE 30, 2017 AND 2016

Unaudited

(Dollars in millions, except per share amounts)

	Quarter						Six Months
	2017			2016			2017			2016
Revenues before provision for doubtful accounts	$	11,806		$	11,081		$	23,189		$	22,131
Provision for doubtful accounts		1,073			762			1,833			1,552
Revenues		10,733			10,319			21,356			20,579
Salaries and benefits		4,896			4,691			9,797			9,393
Supplies		1,795			1,718			3,592			3,432
Other operating expenses		1,965			1,868			3,895			3,721
Equity in earnings of affiliates		(13	)		(10	)		(23	)		(22	)
Depreciation and amortization		521			489			1,042			968
Interest expense		411			427			830			843
Gains on sales of facilities		(2	)		(6	)		(3	)		(5	)
Legal claim costs		—			10			—			22
		9,573			9,187			19,130			18,352
Income before income taxes		1,160			1,132			2,226			2,227
Provision for income taxes		365			341			654			625
Net income		795			791			1,572			1,602
Net income attributable to noncontrolling interests		138			133			256			250
Net income attributable to HCA Healthcare, Inc.	$	657		$	658		$	1,316		$	1,352
Per share data:
Basic earnings per share	$	1.79		$	1.70		$	3.58		$	3.45
Diluted earnings per share	$	1.75		$	1.65		$	3.48		$	3.34
Shares used in earnings per share calculations (in millions):
Basic		365.847			386.406			368.056			391.401
Diluted		375.338			398.659			377.647			404.617

See accompanying notes.

2

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED COMPREHENSIVE INCOME STATEMENTS

FOR THE QUARTERS AND SIX MONTHS ENDED JUNE 30, 2017 AND 2016

Unaudited

(Dollars in millions)

	Quarter						Six Months
	2017			2016			2017			2016
Net income	$	795		$	791		$	1,572		$	1,602
Other comprehensive income (loss) before taxes:
Foreign currency translation		45			(86	)		55			(129	)
Unrealized gains on available-for-sale securities		2			3			5			5
Defined benefit plans		—			—			—			—
Pension costs included in salaries and benefits		4			5			9			9
		4			5			9			9
Change in fair value of derivative financial instruments		(11	)		(32	)		(8	)		(70	)
Interest costs included in interest expense		6			28			13			56
		(5	)		(4	)		5			(14	)
Other comprehensive income (loss) before taxes		46			(82	)		74			(129	)
Income taxes (benefits) related to other comprehensive income items		19			(32	)		29			(50	)
Other comprehensive income (loss)		27			(50	)		45			(79	)
Comprehensive income		822			741			1,617			1,523
Comprehensive income attributable to noncontrolling interests		138			133			256			250
Comprehensive income attributable to HCA Healthcare, Inc.	$	684		$	608		$	1,361		$	1,273

See accompanying notes.

3

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Unaudited

(Dollars in millions)

	June 30, 2017			December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	705		$	646
Accounts receivable, less allowance for doubtful accounts of $5,050 and $4,988		5,782			5,826
Inventories		1,544			1,503
Other		1,306			1,111
		9,337			9,086
Property and equipment, at cost		38,306			37,055
Accumulated depreciation		(21,538	)		(20,703	)
		16,768			16,352
Investments of insurance subsidiaries		352			336
Investments in and advances to affiliates		197			206
Goodwill and other intangible assets		6,771			6,704
Other		1,141			1,074
	$	34,566		$	33,758
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	2,245		$	2,318
Accrued salaries		1,209			1,265
Other accrued expenses		2,104			2,035
Long-term debt due within one year		213			216
		5,771			5,834
Long-term debt, less net debt issuance costs of $179 and $170		31,448			31,160
Professional liability risks		1,144			1,148
Income taxes and other liabilities		1,282			1,249
Stockholders’ deficit:
Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 362,895,000 shares in 2017 and 370,535,900 shares in 2016		4			4
Accumulated other comprehensive loss		(293	)		(338	)
Retained deficit		(6,503	)		(6,968	)
Stockholders’ deficit attributable to HCA Healthcare, Inc.		(6,792	)		(7,302	)
Noncontrolling interests		1,713			1,669
		(5,079	)		(5,633	)
	$	34,566		$	33,758

See accompanying notes.

4

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND 2016

Unaudited

(Dollars in millions)

	2017			2016
Cash flows from operating activities:
Net income	$	1,572		$	1,602
Adjustments to reconcile net income to net cash provided by operating activities:
Increase (decrease) in cash from operating assets and liabilities:
Accounts receivable		(1,752	)		(1,364	)
Provision for doubtful accounts		1,833			1,552
Accounts receivable, net		81			188
Inventories and other assets		(178	)		(176	)
Accounts payable and accrued expenses		(298	)		(102	)
Depreciation and amortization		1,042			968
Income taxes		267			67
Gains on sales of facilities		(3	)		(5	)
Legal claim costs		—			22
Amortization of debt issuance costs		16			18
Share-based compensation		140			129
Other		45			37
Net cash provided by operating activities		2,684			2,748
Cash flows from investing activities:
Purchase of property and equipment		(1,304	)		(1,172	)
Acquisition of hospitals and health care entities		(295	)		(430	)
Disposal of hospitals and health care entities		14			14
Change in investments		(11	)		18
Other		5			15
Net cash used in investing activities		(1,591	)		(1,555	)
Cash flows from financing activities:
Issuances of long-term debt		1,502			3,000
Net change in revolving bank credit facilities		(1,160	)		—
Repayment of long-term debt		(95	)		(2,065	)
Distributions to noncontrolling interests		(248	)		(205	)
Payment of debt issuance costs		(25	)		(24	)
Repurchases of common stock		(966	)		(1,858	)
Other		(42	)		(91	)
Net cash used in financing activities		(1,034	)		(1,243	)
Change in cash and cash equivalents		59			(50	)
Cash and cash equivalents at beginning of period		646			741
Cash and cash equivalents at end of period	$	705		$	691
Interest payments	$	834		$	767
Income tax payments, net	$	387		$	558

See accompanying notes.

5

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Reporting Entity

HCA Healthcare, Inc. (formerly known as HCA Holdings, Inc.) is a holding company whose affiliates own and operate hospitals and related health care entities. The term “affiliates” includes direct and indirect subsidiaries of HCA Healthcare, Inc. and partnerships and joint ventures in which such subsidiaries are partners. At June 30, 2017, these affiliates owned and operated 172 hospitals, 119 freestanding surgery centers and provided extensive outpatient and ancillary services. HCA Healthcare, Inc.’s facilities are located in 20 states and England. The terms “Company,” “HCA,” “we,” “our” or “us,” as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of HCA and the term “employees” refers to employees of affiliates of HCA.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature.

The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $92 million and $93 million for the quarters ended June 30, 2017 and 2016, respectively, and $182 million and $178 million for the six months ended June 30, 2017 and 2016, respectively. Operating results for the quarter and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2016.

6

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenues

Revenues are recorded during the period the health care services are provided, based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans and commercial insurance companies (including plans offered through the health insurance exchanges), and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record a provision for doubtful accounts (based primarily on historical collection experience) related to uninsured accounts to record net self-pay revenues at the estimated amounts we expect to collect. Our revenues from third-party payers, the uninsured and other for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter
	2017			Ratio			2016			Ratio
Medicare	$	2,321			21.6	%	$	2,217			21.5	%
Managed Medicare		1,187			11.1			1,078			10.4
Medicaid		453			4.2			416			4.0
Managed Medicaid		575			5.4			608			5.9
Managed care and other insurers		6,106			56.9			5,759			55.8
International (managed care and other insurers)		269			2.5			324			3.1
		10,911			101.7			10,402			100.7
Uninsured		519			4.8			225			2.2
Other		376			3.5			454			4.4
Revenues before provision for doubtful accounts		11,806			110.0			11,081			107.3
Provision for doubtful accounts		(1,073	)		(10.0	)		(762	)		(7.3	)
Revenues	$	10,733			100.0	%	$	10,319			100.0	%

	Six Months
	2017			Ratio			2016			Ratio
Medicare	$	4,726			22.1	%	$	4,483			21.8	%
Managed Medicare		2,390			11.2			2,182			10.6
Medicaid		826			3.9			843			4.1
Managed Medicaid		1,216			5.7			1,205			5.9
Managed care and other insurers		12,032			56.3			11,461			55.7
International (managed care and other insurers)		538			2.5			641			3.1
		21,728			101.7			20,815			101.2
Uninsured		744			3.5			414			2.0
Other		717			3.4			902			4.4
Revenues before provision for doubtful accounts		23,189			108.6			22,131			107.6
Provision for doubtful accounts		(1,833	)		(8.6	)		(1,552	)		(7.6	)
Revenues	$	21,356			100.0	%	$	20,579			100.0	%

7

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued)

Recent Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) and the International Accounting Standards Board issued a final, converged, principles-based standard on revenue recognition. Companies across all industries will use a five-step model to recognize revenue from customer contracts. The new standard, which replaces nearly all existing revenue recognition guidance, will require significant management judgments and change the way many companies recognize revenue in their financial statements. In July 2015, the FASB decided to defer the effective date of the new revenue standard by one year to annual and interim periods beginning after December 15, 2017 for public entities and permit entities to adopt one year earlier if they choose. The FASB decided, based on its outreach to various stakeholders and continuing amendments to the new revenue standard, that a deferral was necessary to provide adequate time to effectively implement the new standard. We are continuing to evaluate the effects the adoption of this standard will have on our financial statements and financial disclosures. We believe the most significant impact will be to the presentation of our income statement where the provision for doubtful accounts will be recorded as a direct reduction to revenues and will not be presented as a separate line item. We expect to adopt the new standard using the full retrospective application, and we do not currently believe the adoption will have a significant impact on our recognition of net revenues or related disclosures for any period.

In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for most leases. ASU 2016-02 is effective for public business entities for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. ASU 2016-02’s transition provisions will be applied using a modified retrospective approach at the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the provisions of ASU 2016-02 to determine how our financial statements will be affected, and we believe the primary effect of adopting the new standard will be to record right-of-use assets and obligations for our leases currently classified as operating leases.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

NOTE 2 — ACQUISITIONS AND DISPOSITIONS

During the six months ended June 30, 2017, we paid $189 million to acquire three hospital facilities (two of the hospital facilities have effective acquisition dates of July 1, 2017) and $106 million to acquire other nonhospital health care entities. During the six months ended June 30, 2016, we paid $343 million to acquire three hospital facilities and $87 million to acquire other nonhospital health care entities.

During the six months ended June 30, 2017, we received proceeds of $14 million and recognized a net pretax gain of $3 million related to sales of real estate and other investments. During the six months ended June 30, 2016, we received proceeds of $14 million and recognized a net pretax gain of $5 million related to sales of real estate and other investments.

8

HCA HEALTHCARE, INC. (Continued)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 3 — INCOME TAXES

Our liability for unrecognized tax benefits was $420 million, including accrued interest of $46 million, as of June 30, 2017 ($418 million and $45 million, respectively, as of December 31, 2016). Unrecognized tax benefits of $141 million ($137 million as of December 31, 2016) would affect the effective rate, if recognized.

Our provision for income taxes for the quarters ended June 30, 2017 and 2016, included tax benefits of $9 million and $44 million, respectively, and for the six months ended June 30, 2017 and 2016, included tax benefits of $76 million and $118 million, respectively, related to the settlement of employee equity awards. Our provision for income taxes for the quarter and six months ended June 30, 2017 also included $10 million and $12 million, respectively, of reductions in interest expense (net of tax) related to taxing authority examinations.

We are subject to examination by federal, state and foreign taxing authorities. Depending on the resolution of any federal, state and foreign tax disputes, the completion of examinations by federal, state or foreign taxing authorities, or the expiration of statutes of limitation for specific taxing jurisdictions, we believe it is reasonably possible that our liability for unrecognized tax benefits may significantly increase or decrease within the next 12 months. However, we are currently unable to estimate the range of any possible change.

NOTE 4 — EARNINGS PER SHARE

We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards and potential shares, computed using the treasury stock method.

The following table sets forth the computation of basic and diluted earnings per share for the quarters and six months ended June 30, 2017 and 2016 (dollars and shares in millions, except per share amounts):

	Quarter				Six Months
	2017		2016		2017		2016
Net income attributable to HCA Healthcare, Inc.	$	657	$	658	$	1,316	$	1,352
Weighted average common shares outstanding		365.847		386.406		368.056		391.401
Effect of dilutive incremental shares		9.491		12.253		9.591		13.216
Shares used for diluted earnings per share		375.338		398.659		377.647		404.617
Earnings per share:
Basic earnings per share	$	1.79	$	1.70	$	3.58	$	3.45
Diluted earnings per share	$	1.75	$	1.65	$	3.48	$	3.34

9

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES

A summary of our insurance subsidiaries’ investments at June 30, 2017 and December 31, 2016 follows (dollars in millions):

	June 30, 2017
	Amortized Cost		Unrealized Amounts				Fair Value
			Gains		Losses
Debt securities:
States and municipalities	$	364		$14		$—	$	378
Money market funds		20		—		—		20
		384		14		—		398
Equity securities		1		2		—		3
	$	385		$16		$—		401
Amounts classified as current assets								(49	)
Investment carrying value							$	352

	December 31, 2016
	Amortized Cost		Unrealized Amounts				Fair Value
			Gains		Losses
Debt securities:
States and municipalities	$	345		$9		$(1)	$	353
Money market funds		28		—		—		28
		373		9		(1)		381
Equity securities		1		3		—		4
	$	374		$12		$(1)		385
Amounts classified as current assets								(49	)
Investment carrying value							$	336

At June 30, 2017 and December 31, 2016, the investments of our insurance subsidiaries were classified as “available-for-sale.” Changes in temporary unrealized gains and losses are recorded as adjustments to other comprehensive income (loss).

Scheduled maturities of investments in debt securities at June 30, 2017 were as follows (dollars in millions):

	Amortized Cost		Fair Value
Due in one year or less	$	96	$	96
Due after one year through five years		71		74
Due after five years through ten years		174		184
Due after ten years		43		44
	$	384	$	398

The average expected maturity of the investments in debt securities at June 30, 2017 was 3.9 years, compared to the average scheduled maturity of 5.5 years. Expected and scheduled maturities may differ because the issuers of certain securities have the right to call, prepay or otherwise redeem such obligations prior to their scheduled maturity date.

10

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 6 — FINANCIAL INSTRUMENTS

Interest Rate Swap Agreements

We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between two parties based on common notional principal amounts and maturity dates. Pay-fixed interest rate swaps effectively convert LIBOR indexed variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions.

The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at June 30, 2017 (dollars in millions):

	Notional Amount		Maturity Date		Fair Value
Pay-fixed interest rate swaps	$	1,000		December 2017	$	(5	)
Pay-fixed interest rate swaps		2,000		December 2021		29

During the next 12 months, we estimate $8 million will be reclassified from other comprehensive income (“OCI”) to interest expense.

Derivatives — Results of Operations

The following table presents the effect of our interest rate swaps on our results of operations for the six months ended June 30, 2017 (dollars in millions):

Derivatives in Cash Flow Hedging Relationships	Amount of Loss Recognized in OCI on Derivatives, Net of  Tax		Location of Loss Reclassified from Accumulated OCI into Operations		Amount of Loss Reclassified from Accumulated OCI into Operations
Interest rate swaps	$	5		Interest expense	$	13

NOTE 7 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC 820”) emphasizes fair value is a market-based measurement, and fair value measurements should be determined based on the assumptions market participants would use in pricing assets or liabilities. ASC 820 utilizes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

11

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 7 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (continued)

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment.

Cash Traded Investments

Our cash traded investments are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Certain types of cash traded instruments are classified within Level 3 of the fair value hierarchy because they trade infrequently and therefore have little or no price transparency. The valuation of these securities involves the consideration of market factors and management’s judgment.

Derivative Financial Instruments

We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments.

Although we determined the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with our derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. We assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative positions, and at June 30, 2017 and December 31, 2016, we determined the credit valuation adjustments were not significant to the overall valuation of our derivatives.

12

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 7 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (continued)

The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions):

	June 30, 2017
				Fair Value Measurements Using
	Fair Value			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Assets:
Investments of insurance subsidiaries:
Debt securities:
States and municipalities	$	378		$	—		$	378		$	—
Money market funds		20			20			—			—
		398			20			378			—
Equity securities		3			3			—			—
Investments of insurance subsidiaries		401			23			378			—
Less amounts classified as current assets		(49	)		(20	)		(29	)		—
	$	352		$	3		$	349		$	—
Interest rate swaps (Other)	$	29		$	—		$	29		$	—
Liabilities:
Interest rate swaps (Income taxes and other liabilities)	$	5		$	—		$	5		$	—
	December 31, 2016
				Fair Value Measurements Using
	Fair Value			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Assets:
Investments of insurance subsidiaries:
Debt securities:
States and municipalities	$	353		$	—		$	347		$	6
Money market funds		28			28			—			—
		381			28			347			6
Equity securities		4			4			—			—
Investments of insurance subsidiaries		385			32			347			6
Less amounts classified as current assets		(49	)		(28	)		(21	)		—
	$	336		$	4		$	326		$	6
Interest rate swaps (Other)	$	31		$	—		$	31		$	—
Liabilities:
Interest rate swaps (Income taxes and other liabilities)	$	12		$	—		$	12		$	—

13

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 7 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (continued)

The $6 million reduction in the Level 3 investments of our insurance subsidiaries resulted from settlements. The estimated fair value of our long-term debt was $33.802 billion and $32.833 billion at June 30, 2017 and December 31, 2016, respectively, compared to carrying amounts, excluding net debt issuance costs, aggregating $31.840 billion and $31.546 billion, respectively. The estimates of fair value are generally based upon the quoted market prices or quoted market prices for similar issues of long-term debt with the same maturities.

NOTE 8 — LONG-TERM DEBT

A summary of long-term debt at June 30, 2017 and December 31, 2016, including related interest rates at June 30, 2017, follows (dollars in millions):

	June 30, 2017			December 31, 2016
Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)	$	1,760		$	2,920
Senior secured revolving credit facility		—			—
Senior secured term loan facilities (effective interest rate of 3.6%)		3,939			3,981
Senior secured notes (effective interest rate of 5.4%)		15,300			13,800
Other senior secured debt (effective interest rate of 5.8%)		589			593
Senior secured debt		21,588			21,294
Senior unsecured notes (effective interest rate of 6.5%)		10,252			10,252
Net debt issuance costs		(179	)		(170	)
Total debt (average life of 7.3 years, rates averaging 5.4%)		31,661			31,376
Less amounts due within one year		213			216
	$	31,448		$	31,160

2017 Activity

During June 2017, we issued $1.500 billion aggregate principal amount of 5.500% senior secured notes due 2047. We will use the net proceeds for general corporate purposes, which may include funding all or a portion of the purchase price of certain previously announced hospital acquisitions, and the redemption, during the third quarter of 2017, of all $500 million aggregate principal amount of our existing 8.000% senior notes maturing in October 2018.

During June 2017, we amended our senior secured revolving credit facilities by (i) increasing the commitments under the senior secured asset-based revolving credit facility to $3.750 billion, (ii) extending the maturity date of the revolving credit commitments to June 28, 2022, (iii) amending the incremental facility provisions to permit the incurrence of additional incremental credit facilities in an aggregate principal amount of $1.5 billion and (iv) providing that the commitment fee for unutilized commitments under the senior secured asset-based revolving credit facility shall be 0.250% per annum.

2016 Activity

During August 2016, we issued $1.200 billion aggregate principal amount of 4.500% senior secured notes due 2027. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior

14

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 8 — LONG-TERM DEBT (continued)

2016 Activity (continued)

secured term loan using proceeds from a new $1.200 billion senior secured term loan facility maturing in February 2024.

During March 2016, we issued $1.500 billion aggregate principal amount of 5.250% senior secured notes due 2026. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior secured term loan using proceeds from a new $1.500 billion senior secured term loan facility maturing in March 2023.

NOTE 9 — CONTINGENCIES

We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity.

Health care companies are subject to numerous investigations by various governmental agencies. Under the federal False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material, adverse effect on our results of operations, financial position or liquidity.

NOTE 10 — CAPITAL STRUCTURE

The changes in stockholders’ deficit, including changes in stockholders’ deficit attributable to HCA Healthcare, Inc. and changes in equity attributable to noncontrolling interests, are as follows (dollars and shares in millions):

	Equity (Deficit) Attributable to HCA Healthcare, Inc.														Equity Attributable to Noncontrolling Interests			Total
	Common Stock					Capital in Excess of Par Value			Accumulated Other Comprehensive Loss			Retained Deficit
	Shares			Par Value
Balances at December 31, 2016		370.536		$	4	$	—		$	(338	)	$	(6,968	)	$	1,669		$	(5,633	)
Comprehensive income		—			—		—			45			1,316			256			1,617
Repurchase of common stock		(11.525	)		—		(115	)		—			(851	)		—			(966	)
Distributions		—			—		—			—			—			(248	)		(248	)
Share-based benefit plans		3.884			—		117			—			—			—			117
Other		—			—		(2	)		—			—			36			34
Balances at June 30, 2017		362.895		$	4	$	—		$	(293	)	$	(6,503	)	$	1,713		$	(5,079	)

15

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 10 — CAPITAL STRUCTURE (continued)

During the six months ended June 30, 2017, we repurchased 11.525 million shares of our common stock at an average price of $83.81 per share through market purchases pursuant to the $2.0 billion share repurchase program authorized during November 2016. At June 30, 2017, we had $887 million of repurchase authorization available under the November 2016 authorization.

The components of accumulated other comprehensive loss are as follows (dollars in millions):

	Unrealized Gains on Available- for-Sale Securities		Foreign Currency Translation Adjustments			Defined Benefit Plans			Change in Fair Value of Derivative Instruments			Total
Balances at December 31, 2016	$	7	$	(211	)	$	(146	)	$	12		$	(338	)
Unrealized gains on available-for-sale securities, net of $2 of income taxes		3		—			—			—			3
Foreign currency translation adjustments, net of $22 of income taxes		—		33			—			—			33
Change in fair value of derivative instruments, net of $3 income tax benefits		—		—			—			(5	)		(5	)
Expense reclassified into operations from other comprehensive income, net of $3 and $5, respectively, income tax benefits		—		—			6			8			14
Balances at June 30, 2017	$	10	$	(178	)	$	(140	)	$	15		$	(293	)

NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION

We operate in one line of business, which is operating hospitals and related health care entities. We operate in two geographically organized groups: the National and American Groups. The National Group includes 86 hospitals located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia, and the American Group includes 80 hospitals located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. We also operate six hospitals in England, and these facilities are included in the Corporate and other group.

Adjusted segment EBITDA is defined as income before depreciation and amortization, interest expense, gains on sales of facilities, legal claim costs, income taxes and net income attributable to noncontrolling interests. We use adjusted segment EBITDA as an analytical indicator for purposes of allocating resources to geographic areas and assessing their performance. Adjusted segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from adjusted segment EBITDA are significant components in understanding and assessing financial performance. Because adjusted segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The geographic distributions of our revenues, equity in earnings of affiliates,

16

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION (continued)

adjusted segment EBITDA and depreciation and amortization for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter						Six Months
	2017			2016			2017			2016
Revenues:
National Group	$	5,160		$	4,931		$	10,308		$	9,898
American Group		5,093			4,860			10,088			9,646
Corporate and other		480			528			960			1,035
	$	10,733		$	10,319		$	21,356		$	20,579
Equity in earnings of affiliates:
National Group	$	(4	)	$	(2	)	$	(9	)	$	(4	)
American Group		(10	)		(8	)		(18	)		(17	)
Corporate and other		1			—			4			(1	)
	$	(13	)	$	(10	)	$	(23	)	$	(22	)
Adjusted segment EBITDA:
National Group	$	1,162		$	1,131		$	2,293		$	2,269
American Group		1,040			1,004			2,047			1,986
Corporate and other		(112	)		(83	)		(245	)		(200	)
	$	2,090		$	2,052		$	4,095		$	4,055
Depreciation and amortization:
National Group	$	217		$	201		$	431		$	398
American Group		238			225			476			444
Corporate and other		66			63			135			126
	$	521		$	489		$	1,042		$	968
Adjusted segment EBITDA	$	2,090		$	2,052		$	4,095		$	4,055
Depreciation and amortization		521			489			1,042			968
Interest expense		411			427			830			843
Gains on sales of facilities		(2	)		(6	)		(3	)		(5	)
Legal claim costs		—			10			—			22
Income before income taxes	$	1,160		$	1,132		$	2,226		$	2,227

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

During December 2012, HCA Healthcare, Inc. issued $1.000 billion aggregate principal amount of 6.250% senior unsecured notes due 2021. These notes are senior unsecured obligations and are not guaranteed by any of our subsidiaries.

HCA Inc., a direct wholly-owned subsidiary of HCA Healthcare, Inc., is the obligor under a significant portion of our other indebtedness, including our senior secured credit facilities, senior secured notes and senior unsecured notes (other than the senior unsecured notes issued by HCA Healthcare, Inc.). The senior secured notes and senior unsecured notes issued by HCA Inc. are fully and unconditionally guaranteed by HCA Healthcare, Inc. The senior secured credit facilities and senior secured notes are fully and

17

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

unconditionally guaranteed by substantially all existing and future, direct and indirect, 100% owned material domestic subsidiaries that are “Unrestricted Subsidiaries” under our Indenture dated December 16, 1993 (except for certain special purpose subsidiaries that only guarantee and pledge their assets under our senior secured asset-based revolving credit facility).

Our summarized condensed consolidating comprehensive income statements for the quarters and six months ended June 30, 2017 and 2016, condensed consolidating balance sheets at June 30, 2017 and December 31, 2016 and condensed consolidating statements of cash flows for the six months ended June 30, 2017 and 2016, segregating HCA Healthcare, Inc. issuer, HCA Inc. issuer, the subsidiary guarantors, the subsidiary non-guarantors and eliminations, follow:

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE QUARTER ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	6,049		$	5,757		$	—		$	11,806
Provision for doubtful accounts		—			—			593			480			—			1,073
Revenues		—			—			5,456			5,277			—			10,733
Salaries and benefits		—			—			2,437			2,459			—			4,896
Supplies		—			—			931			864			—			1,795
Other operating expenses		4			—			951			1,010			—			1,965
Equity in earnings of affiliates		(658	)		—			(1	)		(12	)		658			(13	)
Depreciation and amortization		—			—			248			273			—			521
Interest expense		16			755			(291	)		(69	)		—			411
Gains on sales of facilities		—			—			(1	)		(1	)		—			(2	)
Management fees		—			—			(212	)		212			—			—
		(638	)		755			4,062			4,736			658			9,573
Income (loss) before income taxes		638			(755	)		1,394			541			(658	)		1,160
Provision (benefit) for income taxes		(19	)		(279	)		505			158			—			365
Net income (loss)		657			(476	)		889			383			(658	)		795
Net income attributable to noncontrolling interests		—			—			27			111			—			138
Net income (loss) attributable to HCA Healthcare, Inc.	$	657		$	(476	)	$	862		$	272		$	(658	)	$	657
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	684		$	(480	)	$	865		$	300		$	(685	)	$	684

18

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE QUARTER ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	5,693		$	5,388		$	—		$	11,081
Provision for doubtful accounts		—			—			498			264			—			762
Revenues		—			—			5,195			5,124			—			10,319
Salaries and benefits		—			—			2,347			2,344			—			4,691
Supplies		—			—			886			832			—			1,718
Other operating expenses		2			—			893			973			—			1,868
Equity in earnings of affiliates		(641	)		—			(1	)		(9	)		641			(10	)
Depreciation and amortization		—			—			238			251			—			489
Interest expense		16			670			(204	)		(55	)		—			427
Gains on sales of facilities		—			—			(2	)		(4	)		—			(6	)
Legal claim costs		—			10			—			—			—			10
Management fees		—			—			(235	)		235			—			—
		(623	)		680			3,922			4,567			641			9,187
Income (loss) before income taxes		623			(680	)		1,273			557			(641	)		1,132
Provision (benefit) for income taxes		(35	)		(251	)		462			165			—			341
Net income (loss)		658			(429	)		811			392			(641	)		791
Net income attributable to noncontrolling interests		—			—			21			112			—			133
Net income (loss) attributable to HCA Healthcare, Inc.	$	658		$	(429	)	$	790		$	280		$	(641	)	$	658
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	608		$	(431	)	$	794		$	228		$	(591	)	$	608

19

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	11,902		$	11,287		$	—		$	23,189
Provision for doubtful accounts		—			—			1,012			821			—			1,833
Revenues		—			—			10,890			10,466			—			21,356
Salaries and benefits		—			—			4,903			4,894			—			9,797
Supplies		—			—			1,882			1,710			—			3,592
Other operating expenses		5			—			1,878			2,012			—			3,895
Equity in earnings of affiliates		(1,266	)		—			(2	)		(21	)		1,266			(23	)
Depreciation and amortization		—			—			499			543			—			1,042
Interest expense		32			1,488			(560	)		(130	)		—			830
Gains on sales of facilities		—			—			(1	)		(2	)		—			(3	)
Management fees		—			—			(422	)		422			—			—
		(1,229	)		1,488			8,177			9,428			1,266			19,130
Income (loss) before income taxes		1,229			(1,488	)		2,713			1,038			(1,266	)		2,226
Provision (benefit) for income taxes		(87	)		(549	)		983			307			—			654
Net income (loss)		1,316			(939	)		1,730			731			(1,266	)		1,572
Net income attributable to noncontrolling interests		—			—			50			206			—			256
Net income (loss) attributable to HCA Healthcare, Inc.	$	1,316		$	(939	)	$	1,680		$	525		$	(1,266	)	$	1,316
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	1,361		$	(936	)	$	1,686		$	561		$	(1,311	)	$	1,361

20

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	11,366		$	10,765		$	—		$	22,131
Provision for doubtful accounts		—			—			992			560			—			1,552
Revenues		—			—			10,374			10,205			—			20,579
Salaries and benefits		—			—			4,701			4,692			—			9,393
Supplies		—			—			1,784			1,648			—			3,432
Other operating expenses		4			—			1,750			1,967			—			3,721
Equity in earnings of affiliates		(1,270	)		—			(3	)		(19	)		1,270			(22	)
Depreciation and amortization		—			—			465			503			—			968
Interest expense		32			1,320			(411	)		(98	)		—			843
Gains on sales of facilities		—			—			—			(5	)		—			(5	)
Legal claim costs		—			22			—			—			—			22
Management fees		—			—			(395	)		395			—			—
		(1,234	)		1,342			7,891			9,083			1,270			18,352
Income (loss) before income taxes		1,234			(1,342	)		2,483			1,122			(1,270	)		2,227
Provision (benefit) for income taxes		(118	)		(495	)		900			338			—			625
Net income (loss)		1,352			(847	)		1,583			784			(1,270	)		1,602
Net income attributable to noncontrolling interests		—			—			43			207			—			250
Net income (loss) attributable to HCA Healthcare, Inc.	$	1,352		$	(847	)	$	1,540		$	577		$	(1,270	)	$	1,352
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	1,273		$	(856	)	$	1,546		$	501		$	(1,191	)	$	1,273

21

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING BALANCE SHEET

JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors		Eliminations			Condensed Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—		$	—		$	155		$	550	$	—		$	705
Accounts receivable, net		—			—			2,991			2,791		—			5,782
Inventories		—			—			923			621		—			1,544
Other		—			—			522			784		—			1,306
		—			—			4,591			4,746		—			9,337
Property and equipment, net		—			—			8,560			8,208		—			16,768
Investments of insurance subsidiaries		—			—			—			352		—			352
Investments in and advances to affiliates		28,356			—			15			182		(28,356	)		197
Goodwill and other intangible assets		—			—			1,727			5,044		—			6,771
Other		805			29			33			274		—			1,141
	$	29,161		$	29		$	14,926		$	18,806	$	(28,356	)	$	34,566
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	—		$	—		$	1,342		$	903	$	—		$	2,245
Accrued salaries		—			—			679			530		—			1,209
Other accrued expenses		281			383			457			983		—			2,104
Long-term debt due within one year		—			97			57			59		—			213
		281			480			2,535			2,475		—			5,771
Long-term debt, net		994			29,981			188			285		—			31,448
Intercompany balances		34,258			(9,404	)		(27,765	)		2,911		—			—
Professional liability risks		—			—			—			1,144		—			1,144
Income taxes and other liabilities		420			5			403			454		—			1,282
		35,953			21,062			(24,639)			7,269		—			39,645
Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc.		(6,792	)		(21,033	)		39,438			9,951		(28,356	)		(6,792	)
Noncontrolling interests		—			—			127			1,586		—			1,713
		(6,792	)		(21,033	)		39,565			11,537		(28,356	)		(5,079	)
	$	29,161		$	29		$	14,926		$	18,806	$	(28,356	)	$	34,566

22

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING BALANCE SHEET

DECEMBER 31, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors		Eliminations			Condensed Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—		$	—		$	110		$	536	$	—		$	646
Accounts receivable, net		—			—			3,028			2,798		—			5,826
Inventories		—			—			890			613		—			1,503
Other		—			—			445			666		—			1,111
		—			—			4,473			4,613		—			9,086
Property and equipment, net		—			—			8,463			7,889		—			16,352
Investments of insurance subsidiaries		—			—			—			336		—			336
Investments in and advances to affiliates		27,045			—			16			190		(27,045	)		206
Goodwill and other intangible assets		—			—			1,728			4,976		—			6,704
Other		877			—			34			163		—			1,074
	$	27,922		$	—		$	14,714		$	18,167	$	(27,045	)	$	33,758
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	—		$	—		$	1,439		$	879	$	—		$	2,318
Accrued salaries		—			—			704			561		—			1,265
Other accrued expenses		29			572			464			970		—			2,035
Long-term debt due within one year		—			97			60			59		—			216
		29			669			2,667			2,469		—			5,834
Long-term debt, net		993			29,693			199			275		—			31,160
Intercompany balances		33,784			(10,277	)		(26,447	)		2,940		—			—
Professional liability risks		—			—			—			1,148		—			1,148
Income taxes and other liabilities		418			12			387			432		—			1,249
		35,224			20,097			(23,194	)		7,264		—			39,391
Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc.		(7,302	)		(20,097	)		37,752			9,390		(27,045	)		(7,302	)
Noncontrolling interests		—			—			156			1,513		—			1,669
		(7,302	)		(20,097	)		37,908			10,903		(27,045	)		(5,633	)
	$	27,922		$	—		$	14,714		$	18,167	$	(27,045	)	$	33,758

23

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Cash flows from operating activities:
Net income (loss)	$	1,316		$	(939	)	$	1,730		$	731		$	(1,266	)	$	1,572
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities		1			(189	)		(1,189	)		(851	)		—			(2,228	)
Provision for doubtful accounts		—			—			1,012			821			—			1,833
Depreciation and amortization		—			—			499			543			—			1,042
Income taxes		267			—			—			—			—			267
Gains on sales of facilities		—			—			(1	)		(2	)		—			(3	)
Amortization of debt issuance costs		—			16			—			—			—			16
Share-based compensation		—			—			140			—			—			140
Equity in earnings of affiliates		(1,266	)		—			—			—			1,266			—
Other		39			—			—			6			—			45
Net cash provided by (used in) operating activities		357			(1,112	)		2,191			1,248			—			2,684
Cash flows from investing activities:
Purchase of property and equipment		—			—			(578	)		(726	)		—			(1,304	)
Acquisition of hospitals and health care entities		—			—			(5	)		(290	)		—			(295	)
Disposition of hospitals and health care entities		—			—			10			4			—			14
Change in investments		—			—			—			(11	)		—			(11	)
Other		—			—			2			3			—			5
Net cash used in investing activities		—			—			(571	)		(1,020	)		—			(1,591	)
Cash flows from financing activities:
Issuance of long-term debt		—			1,500			—			2			—			1,502
Net change in revolving credit facilities		—			(1,160	)		—			—			—			(1,160	)
Repayment of long-term debt		—			(42	)		(33	)		(20	)		—			(95	)
Distributions to noncontrolling interests		—			—			(79	)		(169	)		—			(248	)
Payment of debt issuance costs		—			(25	)		—			—			—			(25	)
Repurchases of common stock		(966	)		—			—			—			—			(966	)
Changes in intercompany balances with affiliates, net		671			839			(1,463	)		(47	)		—			—
Other		(62	)		—			—			20			—			(42	)
Net cash (used in) provided by financing activities		(357	)		1,112			(1,575	)		(214	)		—			(1,034	)
Change in cash and cash equivalents		—			—			45			14			—			59
Cash and cash equivalents at beginning of period		—			—			110			536			—			646
Cash and cash equivalents at end of period	$	—		$	—		$	155		$	550		$	—		$	705

24

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION (continued)

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Cash flows from operating activities:
Net income (loss)	$	1,352		$	(847	)	$	1,583		$	784		$	(1,270	)	$	1,602
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities		(23	)		66			(1,140	)		(545	)		—			(1,642	)
Provision for doubtful accounts		—			—			992			560			—			1,552
Depreciation and amortization		—			—			465			503			—			968
Income taxes		67			—			—			—			—			67
Gains on sales of facilities		—			—			—			(5	)		—			(5	)
Legal claim costs		—			22			—			—			—			22
Amortization of debt issuance costs		—			18			—			—			—			18
Share-based compensation		—			—			129			—			—			129
Equity in earnings of affiliates		(1,270	)		—			—			—			1,270			—
Other		37			—			(2	)		2			—			37
Net cash provided by (used in) operating activities		163			(741	)		2,027			1,299			—			2,748
Cash flows from investing activities:
Purchase of property and equipment		—			—			(482	)		(690	)		—			(1,172	)
Acquisition of hospitals and health care entities		—			—			(148	)		(282	)		—			(430	)
Disposition of hospitals and health care entities		—			—			9			5			—			14
Change in investments		—			—			3			15			—			18
Other		—			—			(1	)		16			—			15
Net cash used in investing activities		—			—			(619	)		(936	)		—			(1,555	)
Cash flows from financing activities:
Issuance of long-term debt		—			3,000			—			—			—			3,000
Repayment of long-term debt		—			(2,005	)		(38	)		(22	)		—			(2,065	)
Distributions to noncontrolling interests		—			—			(29	)		(176	)		—			(205	)
Payment of debt issuance costs		—			(24	)		—			—			—			(24	)
Repurchases of common stock		(1,858	)		—			—			—			—			(1,858	)
Changes in intercompany balances with affiliates, net		1,799			(230	)		(1,414	)		(155	)		—			—
Other		(104	)		—			—			13			—			(91	)
Net cash (used in) provided by financing activities		(163	)		741			(1,481	)		(340	)		—			(1,243	)
Change in cash and cash equivalents		—			—			(73	)		23			—			(50	)
Cash and cash equivalents at beginning of period		—			—			155			586			—			741
Cash and cash equivalents at end of period	$	—		$	—		$	82		$	609		$	—		$	691

25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This quarterly report on Form 10-Q includes certain disclosures which contain “forward-looking statements.” Forward-looking statements include statements regarding expected share-based compensation expense, expected capital expenditures and expected net claim payments and all other statements that do not relate solely to historical or current facts, and can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (2) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Health Reform Law”), including the effects of any repeal of, or changes to, the Health Reform Law, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, (3) the effects related to the continued implementation of the sequestration spending reductions required under the Budget Control Act of 2011, and related legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (4) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (5) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (6) possible changes in Medicare, Medicaid and other state programs, including Medicaid upper payment limit programs or Waiver Programs, that may impact reimbursements to health care providers and insurers, (7) the highly competitive nature of the health care business, (8) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under managed care agreements, the ability to enter into and renew managed care provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (9) the efforts of insurers, health care providers and others to contain health care costs, (10) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (11) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (12) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (13) changes in accounting practices, (14) changes in general economic conditions nationally and regionally in our markets, (15) the emergence and effects related to infectious diseases, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of potential cybersecurity incidents or security breaches, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record (“EHR”) technology, and (23) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2016 and our other filings with the Securities and Exchange Commission. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ from those expressed in any forward-looking statements made by or on behalf of HCA. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this report, which forward-looking statements reflect management’s views only as of the date of this report. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise.

26

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Second Quarter 2017 Operations Summary

Revenues increased to $10.733 billion in the second quarter of 2017 from $10.319 billion in the second quarter of 2016. Net income attributable to HCA Healthcare, Inc. totaled $657 million, or $1.75 per diluted share, for the quarter ended June 30, 2017, compared to $658 million, or $1.65 per diluted share, for the quarter ended June 30, 2016. Second quarter 2017 results include net gains on sales of facilities of $2 million. Second quarter 2016 results include legal claim costs of $10 million, or $0.02 per diluted share, and net gains on sales of facilities of $6 million, or $0.01 per diluted share. Our provisions for income taxes for the second quarters of 2017 and 2016 included tax benefits of $9 million, or $0.02 per diluted share, and $44 million, or $0.11 per diluted share, respectively, related to excess tax benefits from employee equity award settlements. All “per diluted share” disclosures are based upon amounts net of the applicable income taxes. Shares used for diluted earnings per share were 375.338 million shares for the quarter ended June 30, 2017 and 398.659 million shares for the quarter ended June 30, 2016. During 2016 and the first six months of 2017, we repurchased 36.325 million shares and 11.525 million shares of our common stock, respectively.

Revenues increased 4.0% on a consolidated basis and increased 3.4% on a same facility basis for the quarter ended June 30, 2017, compared to the quarter ended June 30, 2016. The increase in consolidated revenues can be attributed to the combined impact of a 1.9% increase in revenue per equivalent admission and a 2.1% increase in equivalent admissions. The same facility revenues increase resulted from the combined impact of a 2.0% increase in same facility revenue per equivalent admission and a 1.3% increase in same facility equivalent admissions.

During the quarters ended June 30, 2017 and 2016, consolidated admissions and same facility admissions increased 1.3% and 0.8%, respectively. Surgeries were flat on a consolidated basis and declined 0.9% on a same facility basis during the quarter ended June 30, 2017, compared to the quarter ended June 30, 2016. Emergency department visits increased 1.1% on a consolidated basis and increased 0.4% on a same facility basis during the quarter ended June 30, 2017, compared to the quarter ended June 30, 2016.

For the quarter ended June 30, 2017, the provision for doubtful accounts increased $311 million, compared to the quarter ended June 30, 2016. The self-pay revenue deductions for charity care and uninsured discounts increased $74 million and $360 million, respectively, during the second quarter of 2017, compared to the second quarter of 2016. The sum of the provision for doubtful accounts, uninsured discounts and charity care, as a percentage of the sum of revenues, provision for doubtful accounts, uninsured discounts and charity care, was 34.8% for the second quarter of 2017, compared to 32.5% for the second quarter of 2016. Same facility uninsured admissions increased 4.9% for the quarter ended June 30, 2017, compared to the quarter ended June 30, 2016.

Cash flows from operating activities increased $55 million from $1.349 billion for the second quarter of 2016 to $1.404 billion for the second quarter of 2017. The increase relates primarily to the net impact of net negative changes in working capital items of $241 million and $268 million of favorable changes in income taxes.

Results of Operations

Revenue/Volume Trends

Our revenues depend upon inpatient occupancy levels, the ancillary services and therapy programs ordered by physicians and provided to patients, the volume of outpatient procedures and the charge and negotiated payment rates for such services. Gross charges typically do not reflect what our facilities are actually paid. Our facilities have entered into agreements with third-party payers, including government programs and managed care health plans, under which the facilities are paid based upon the cost of providing services, predetermined rates per diagnosis, fixed per diem rates or discounts from gross charges. We do not pursue collection of amounts

27

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Revenue/Volume Trends (continued)

related to patients who meet our guidelines to qualify for charity care; therefore, they are not reported in revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. After the discounts are applied, we are still unable to collect a significant portion of uninsured patients’ accounts, and we record provisions for doubtful accounts (based upon our historical collection experience) related to uninsured patients in the period the services are provided to record the net self-pay revenues at the estimated amounts we expect to collect.

Revenues increased 4.0% from $10.319 billion in the second quarter of 2016 to $10.733 billion in the second quarter of 2017. Our international revenues declined 17.4% from $324 million in the second quarter of 2016 to $269 million in the second quarter of 2017. Declines in admissions related to patients from certain Middle-Eastern countries seeking health care services in England, admissions related to private medical insurance patients and in the currency translation rates have contributed to the decline in international revenues.

Revenues are recorded during the period the health care services are provided, based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans and commercial insurance companies (including plans offered through the health insurance exchanges), and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). Our revenues from our third-party payers, the uninsured and other payers for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter
	2017			Ratio			2016			Ratio
Medicare	$	2,321			21.6	%	$	2,217			21.5	%
Managed Medicare		1,187			11.1			1,078			10.4
Medicaid		453			4.2			416			4.0
Managed Medicaid		575			5.4			608			5.9
Managed care and other insurers		6,106			56.9			5,759			55.8
International (managed care and other insurers)		269			2.5			324			3.1
		10,911			101.7			10,402			100.7
Uninsured		519			4.8			225			2.2
Other		376			3.5			454			4.4
Revenues before provision for doubtful accounts		11,806			110.0			11,081			107.3
Provision for doubtful accounts		(1,073	)		(10.0	)		(762	)		(7.3	)
Revenues	$	10,733			100.0	%	$	10,319			100.0	%

28

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Revenue/Volume Trends (continued)

	Six Months
	2017			Ratio			2016			Ratio
Medicare	$	4,726			22.1	%	$	4,483			21.8	%
Managed Medicare		2,390			11.2			2,182			10.6
Medicaid		826			3.9			843			4.1
Managed Medicaid		1,216			5.7			1,205			5.9
Managed care and other insurers		12,032			56.3			11,461			55.7
International (managed care and other insurers)		538			2.5			641			3.1
		21,728			101.7			20,815			101.2
Uninsured		744			3.5			414			2.0
Other		717			3.4			902			4.4
Revenues before provision for doubtful accounts		23,189			108.6			22,131			107.6
Provision for doubtful accounts		(1,833	)		(8.6	)		(1,552	)		(7.6	)
Revenues	$	21,356			100.0	%	$	20,579			100.0	%

Consolidated and same facility revenue per equivalent admission increased 1.9% and 2.0%, respectively, in the second quarter of 2017, compared to the second quarter of 2016. Consolidated and same facility equivalent admissions increased 2.1% and 1.3%, respectively, in the second quarter of 2017, compared to the second quarter of 2016. Consolidated and same facility outpatient surgeries declined 0.2% and 1.2%, respectively, in the second quarter of 2017, compared to the second quarter of 2016. Consolidated inpatient surgeries increased 0.4% and same facility inpatient surgeries were flat in the second quarter of 2017, compared to the second quarter of 2016. Consolidated and same facility emergency department visits increased 1.1% and 0.4%, respectively, in the second quarter of 2017, compared to the second quarter of 2016.

To quantify the total impact of and trends related to uninsured accounts, we believe it is beneficial to view the direct uninsured revenue deductions (charity care and uninsured discounts) and provision for doubtful accounts in combination, rather than each separately. At June 30, 2017, our allowance for doubtful accounts represented 99.3% of the $5.086 billion total patient due accounts receivable balance. The patient due accounts receivable balance represents the estimated uninsured portion of our accounts receivable. A summary of these adjustments to revenues amounts, related to uninsured accounts, for the quarters and six months ended June 30, 2017 and 2016 follows (dollars in millions):

	Quarter										Six Months
	2017		Ratio			2016		Ratio			2017		Ratio			2016		Ratio
Charity care	$	1,173		20	%	$	1,099		22	%	$	2,259		20	%	$	2,054		21	%
Uninsured discounts		3,475		61			3,115		63			6,956		63			6,212		63
Provision for doubtful accounts		1,073		19			762		15			1,833		17			1,552		16
Totals	$	5,721		100	%	$	4,976		100	%	$	11,048		100	%	$	9,818		100	%

Same facility uninsured admissions increased by 1,732 admissions, or 4.9%, in the second quarter of 2017, compared to the second quarter of 2016. Same facility uninsured admissions increased by 3.2%, in the first quarter of 2017, compared to the first quarter of 2016. Same facility uninsured admissions in 2016, compared to 2015, declined 0.3% in the fourth quarter of 2016, increased 0.7% in the third quarter of 2016, increased 5.7% in the second quarter of 2016 and increased 10.6% in the first quarter of 2016.

29

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Revenue/Volume Trends (continued)

The approximate percentages of our admissions related to Medicare, managed Medicare, Medicaid, managed Medicaid, managed care and other insurers and the uninsured for the quarters and six months ended June 30, 2017 and 2016 are set forth in the following table.

	Quarter						Six Months
	2017			2016			2017			2016
Medicare		30	%		31	%		31	%		31	%
Managed Medicare		16			15			16			15
Medicaid		5			6			5			6
Managed Medicaid		12			12			12			12
Managed care and other insurers		29			29			28			29
Uninsured		8			7			8			7
		100	%		100	%		100	%		100	%

The approximate percentages of our inpatient revenues, before provision for doubtful accounts, related to Medicare, managed Medicare, Medicaid, managed Medicaid, managed care and other insurers and the uninsured for the quarters and six months ended June 30, 2017 and 2016 are set forth in the following table.

	Quarter						Six Months
	2017			2016			2017			2016
Medicare		27	%		28	%		28	%		28	%
Managed Medicare		12			12			12			12
Medicaid		6			6			6			6
Managed Medicaid		5			6			5			6
Managed care and other insurers		47			48			48			48
Uninsured		3			—			1			—
		100	%		100	%		100	%		100	%

At June 30, 2017, we had 84 hospitals in the states of Texas and Florida. During the second quarter of 2017, 55% of our admissions and 47% of our revenues were generated by these hospitals. Uninsured admissions in Texas and Florida represented 69% of our uninsured admissions during the second quarter of 2017.

We receive a significant portion of our revenues from government health programs, principally Medicare and Medicaid, which are highly regulated and subject to frequent and substantial changes. In 2011, the Centers for Medicare & Medicaid Services (“CMS”) approved a Medicaid waiver that allows Texas to continue receiving supplemental Medicaid reimbursement while expanding its Medicaid managed care program. Texas currently operates its Medicaid Waiver Program pursuant to this waiver, which CMS has agreed to extend through December 2017. We cannot predict whether the Texas Medicaid Waiver Program will be further extended, be revised or that revenues recognized from the program will not decline.

The Texas Medicaid Waiver Program includes two primary components: an indigent care component and a Delivery System Reform Incentive Payment (“DSRIP”) component. Initiatives under the DSRIP program are designed to provide incentive payments to hospitals and other providers for their investments in delivery system reforms that increase access to health care, improve the quality of care and enhance the health of patients and families they serve. We provide indigent care services in several communities in the state of Texas, in affiliation with other hospitals. The state of Texas has been involved in efforts to increase the indigent care provided by private hospitals. As a result of additional indigent care being provided by private hospitals, public hospital

30

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Revenue/Volume Trends (continued)

districts or counties in Texas have available funds that were previously devoted to indigent care. The public hospital districts or counties are under no contractual or legal obligation to provide such indigent care. The public hospital districts or counties have elected to transfer some portion of these available funds to the state’s Medicaid program. Such action is at the sole discretion of the public hospital districts or counties. It is anticipated that these contributions to the state will be matched with federal Medicaid funds. The state then may make supplemental payments to hospitals in the state for Medicaid services rendered. Hospitals receiving Medicaid supplemental payments may include those that are providing additional indigent care services. Our Texas Medicaid revenues included Medicaid supplemental payments of $95 million ($26 million DSRIP related and $69 million indigent care related) and $82 million ($25 million DSRIP related and $57 million indigent care related) during the second quarters of 2017 and 2016, respectively, and $201 million ($56 million DSRIP related and $145 million indigent care related) and $184 million ($53 million DSRIP related and $131 million indigent care related) during the first six months of 2017 and 2016, respectively.

In addition, we receive supplemental payments in several other states. We are aware these supplemental payment programs are currently being reviewed by certain state agencies and CMS, and some states have made waiver requests to CMS to replace their existing supplemental payment programs. It is possible these reviews and waiver requests will result in the restructuring of such supplemental payment programs and could result in the payment programs being reduced or eliminated. Because deliberations about these programs are ongoing, we are unable to estimate the financial impact the program structure modifications, if any, may have on our results of operations.

31

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Operating Results Summary

The following is a comparative summary of results of operations for the quarters and six months ended June 30, 2017 and 2016 (dollars in millions):

	Quarter
	2017						2016
	Amount			Ratio			Amount			Ratio
Revenues before provision for doubtful accounts	$	11,806					$	11,081
Provision for doubtful accounts		1,073						762
Revenues		10,733			100.0			10,319			100.0
Salaries and benefits		4,896			45.6			4,691			45.5
Supplies		1,795			16.7			1,718			16.7
Other operating expenses		1,965			18.3			1,868			18.0
Equity in earnings of affiliates		(13	)		(0.1	)		(10	)		(0.1	)
Depreciation and amortization		521			4.9			489			4.8
Interest expense		411			3.8			427			4.1
Gains on sales of facilities		(2	)		—			(6	)		(0.1	)
Legal claim costs		—			—			10			0.1
		9,573			89.2			9,187			89.0
Income before income taxes		1,160			10.8			1,132			11.0
Provision for income taxes		365			3.4			341			3.3
Net income		795			7.4			791			7.7
Net income attributable to noncontrolling interests		138			1.3			133			1.3
Net income attributable to HCA Healthcare, Inc.	$	657			6.1		$	658			6.4
% changes from prior year:
Revenues		4.0	%					4.3	%
Income before income taxes		2.5						15.0
Net income attributable to HCA Healthcare, Inc.		(0.2	)					29.8
Admissions(a)		1.3						0.6
Equivalent admissions(b)		2.1						1.9
Revenue per equivalent admission		1.9						2.4
Same facility % changes from prior year(c):
Revenues		3.4						3.7
Admissions(a)		0.8						0.6
Equivalent admissions(b)		1.3						1.6
Revenue per equivalent admission		2.0						2.1

32

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Operating Results Summary (continued)

	Six Months
	2017						2016
	Amount			Ratio			Amount			Ratio
Revenues before provision for doubtful accounts	$	23,189					$	22,131
Provision for doubtful accounts		1,833						1,552
Revenues		21,356			100.0			20,579			100.0
Salaries and benefits		9,797			45.9			9,393			45.6
Supplies		3,592			16.8			3,432			16.7
Other operating expenses		3,895			18.2			3,721			18.1
Equity in earnings of affiliates		(23	)		(0.1	)		(22	)		(0.1	)
Depreciation and amortization		1,042			4.9			968			4.7
Interest expense		830			3.9			843			4.1
Gains on sales of facilities		(3	)		—			(5	)		—
Legal claim costs		—			—			22			0.1
		19,130			89.6			18,352			89.2
Income before income taxes		2,226			10.4			2,227			10.8
Provision for income taxes		654			3.0			625			3.0
Net income		1,572			7.4			1,602			7.8
Net income attributable to noncontrolling interests		256			1.2			250			1.2
Net income attributable to HCA Healthcare, Inc.	$	1,316			6.2		$	1,352			6.6
% changes from prior year:
Revenues		3.8	%					5.1	%
Income before income taxes		—						8.0
Net income attributable to HCA Healthcare, Inc.		(2.7	)					23.1
Admissions(a)		1.3						1.3
Equivalent admissions(b)		1.9						2.8
Revenue per equivalent admission		1.8						2.3
Same facility % changes from prior year(c):
Revenues		3.3						4.6
Admissions(a)		1.0						1.1
Equivalent admissions(b)		1.5						2.4
Revenue per equivalent admission		1.8						2.1

(a) Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume.

(b) Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and then dividing the resulting amount by gross inpatient revenues. The equivalent admissions computation “equates” outpatient revenues to the volume measure (admissions) used to measure inpatient volume, resulting in a general measure of combined inpatient and outpatient volume.

(c) Same facility information excludes the operations of hospitals and their related facilities which were either acquired or divested during the current and prior period.

33

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Quarters Ended June 30, 2017 and 2016

Net income attributable to HCA Healthcare, Inc. totaled $657 million, or $1.75 per diluted share, for the second quarter of 2017, compared to $658 million, or $1.65 per diluted share, for the second quarter of 2016. Second quarter 2017 results include net gains on sales of facilities of $2 million. Second quarter 2016 results include legal claim costs of $10 million, or $0.02 per diluted share, and net gains on sales of facilities of $6 million, or $0.01 per diluted share. All “per diluted share” disclosures are based upon amounts net of the applicable income taxes. Shares used for diluted earnings per share were 375.338 million shares for the quarter ended June 30, 2017 and 398.659 million shares for the quarter ended June 30, 2016. During 2016 and the first six months of 2017, we repurchased 36.325 million and 11.525 million shares of our common stock, respectively.

Revenues before provision for doubtful accounts increased 6.5% for the second quarter of 2017 compared to the second quarter of 2016. The provision for doubtful accounts increased $311 million, from $762 million in the second quarter of 2016 to $1.073 billion in the second quarter of 2017. The provision for doubtful accounts relates primarily to uninsured amounts due directly from patients, including copayment and deductible amounts for patients who have health care coverage. The self-pay revenue deductions for charity care and uninsured discounts increased $74 million and $360 million, respectively, during the second quarter of 2017, compared to the second quarter of 2016. The sum of the provision for doubtful accounts, uninsured discounts and charity care, as a percentage of the sum of revenues, the provision for doubtful accounts, uninsured discounts and charity care, was 34.8% for the second quarter of 2017, compared to 32.5% for the second quarter of 2016. At June 30, 2017, our allowance for doubtful accounts represented 99.3% of the $5.086 billion total patient due accounts receivable balance, including accounts, net of estimated contractual discounts, related to patients for which eligibility for Medicaid coverage or uninsured discounts was being evaluated.

Revenues increased 4.0% due to the combined impact of revenue per equivalent admission growth of 1.9% and a 2.1% increase in equivalent admissions for the second quarter of 2017 compared to the second quarter of 2016. Same facility revenues increased 3.4% due to the combined impact of a 2.0% increase in same facility revenue per equivalent admission and a 1.3% increase in same facility equivalent admissions for the second quarter of 2017 compared to the second quarter of 2016.

Salaries and benefits, as a percentage of revenues, were 45.6% in the second quarter of 2017 and 45.5% in the second quarter of 2016. Salaries and benefits per equivalent admission increased 2.2% in the second quarter of 2017 compared to the second quarter of 2016. Same facility labor rate increases averaged 2.6% for the second quarter of 2017 compared to the second quarter of 2016.

Supplies, as a percentage of revenues, were 16.7% in each of the second quarters of 2017 and 2016. Supply costs per equivalent admission increased 2.3% in the second quarter of 2017 compared to the second quarter of 2016. Supply costs per equivalent admission increased 5.0% for medical devices, 1.0% for pharmacy supplies and 0.9% for general medical and surgical items in the second quarter of 2017 compared to the second quarter of 2016.

Other operating expenses, as a percentage of revenues, were 18.3% in the second quarter of 2017 and 18.0% in the second quarter of 2016. Other operating expenses is primarily comprised of contract services, professional fees, repairs and maintenance, rents and leases, utilities, insurance (including professional liability insurance) and nonincome taxes. Provisions for losses related to professional liability risks were $118 million and $111 million for the second quarters of 2017 and 2016, respectively.

Equity in earnings of affiliates was $13 million and $10 million in the second quarters of 2017 and 2016, respectively.

34

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Quarters Ended June 30, 2017 and 2016 (continued)

Depreciation and amortization increased $32 million, from $489 million in the second quarter of 2016 to $521 million in the second quarter of 2017. The increase in depreciation relates primarily to increased routine capital expenditures.

Interest expense was $411 million in the second quarter of 2017 and $427 million in the second quarter of 2016. Our average debt balance was $31.685 billion for the second quarter of 2017 compared to $31.117 billion for the second quarter of 2016. The average effective interest rate for our long-term debt declined to 5.2% from 5.5% for the quarters ended June 30, 2017 and 2016, respectively.

During the second quarters of 2017 and 2016, we recorded net gains on sales of facilities of $2 million and $6 million, respectively.

We recorded $10 million of legal claim costs during the second quarter of 2016 related to the Health Midwest litigation.

The effective tax rates were 35.8% and 34.1% for the second quarters of 2017 and 2016, respectively. The effective tax rate computations exclude net income attributable to noncontrolling interests as it relates to consolidated partnerships. Our provisions for income taxes for the second quarters of 2017 and 2016 included tax benefits of $9 million and $44 million, respectively, related to excess tax benefits from employee equity award settlements. Our provision for income taxes for the second quarter of 2017 also included $10 million of reductions in interest expense (net of tax) related to taxing authority examinations. Excluding the effect of these adjustments, the effective tax rate for the second quarters of 2017 and 2016 would have been 37.8% and 38.5%, respectively.

Net income attributable to noncontrolling interests increased from $133 million for the second quarter of 2016 to $138 million for the second quarter of 2017. The increase in net income attributable to noncontrolling interests related primarily to our health care group purchasing organization.

Six Months Ended June 30, 2017 and 2016

Net income attributable to HCA Healthcare, Inc. totaled $1.316 billion, or $3.48 per diluted share, in the six months ended June 30, 2017 compared to $1.352 billion, or $3.34 per diluted share, in the six months ended June 30, 2016. The first six months of 2017 results include net gains on sales of facilities of $3 million. The first six months of 2016 results include legal claim costs of $22 million, or $0.03 per diluted share, and net gains on sales of facilities of $5 million. All “per diluted share” disclosures are based upon amounts net of the applicable income taxes. Shares used for diluted earnings per share were 377.647 million shares and 404.617 million shares for the six months ended June 30, 2017 and 2016, respectively. During 2016 and the first six months of 2017, we repurchased 36.325 million and 11.525 million shares of our common stock, respectively.

For the first six months of 2017, consolidated and same facility admissions increased 1.3% and 1.0%, respectively, compared to the first six months of 2016. Consolidated and same facility outpatient surgical volumes declined 0.2% and 0.9%, respectively, during the first six months of 2017, compared to the first six months of 2016. Consolidated and same facility inpatient surgeries increased 0.7% and 0.4%, respectively, in the first six months of 2017, compared to the first six months of 2016. Consolidated and same facility emergency department visits increased 1.3% and 0.8%, respectively, during the six months ended June 30, 2017, compared to the six months ended June 30, 2016.

Revenues before provision for doubtful accounts increased 4.8% for the first six months of 2017 compared to the first six months of 2016. Provision for doubtful accounts increased $281 million from $1.552 billion in the

35

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Six Months Ended June 30, 2017 and 2016 (continued)

first six months of 2016 to $1.833 billion in the first six months of 2017. The provision for doubtful accounts relates primarily to uninsured amounts due directly from patients, including copayment and deductible amounts for patients who have health care coverage. The self-pay revenue deductions for charity care and uninsured discounts increased $205 million and $744 million, respectively, during the first six months of 2017, compared to the first six months of 2016. The sum of the provision for doubtful accounts, uninsured discounts and charity care, as a percentage of the sum of revenues, the provision for doubtful accounts, uninsured discounts and charity care, was 34.1% for the first six months of 2017, compared to 32.3% for the first six months of 2016. At June 30, 2017, our allowance for doubtful accounts represented approximately 99.3% of the $5.086 billion total patient due accounts receivable balance, including accounts, net of estimated contractual discounts, related to patients for which eligibility for Medicaid coverage or uninsured discounts was being evaluated.

Revenues increased 3.8% primarily due to the combined impact of revenue per equivalent admission growth of 1.8% and an increase of 1.9% in equivalent admissions for the first six months of 2017 compared to the first six months of 2016. Same facility revenues increased 3.3% due to the combined impact of a 1.8% increase in same facility revenue per equivalent admission and a 1.5% increase in same facility equivalent admissions for the first six months of 2017 compared to the first six months of 2016.

Salaries and benefits, as a percentage of revenues, were 45.9% in the first six months of 2017 and 45.6% in the first six months of 2016. Salaries and benefits per equivalent admission increased 2.3% in the first six months of 2017 compared to the first six months of 2016. Same facility labor rate increases averaged 2.5% for the first six months of 2017 compared to the first six months of 2016.

Supplies, as a percentage of revenues, were 16.8% in the first six months of 2017 and 16.7% in the first six months of 2016. Supply cost per equivalent admission increased 2.6% in the first six months of 2017 compared to the first six months of 2016. Supply costs per equivalent admission increased 6.1% for medical devices and 1.5% for general medical and surgical items and declined 0.3% for pharmacy supplies in the first six months of 2017 compared to the first six months of 2016.

Other operating expenses, as a percentage of revenues, increased to 18.2% in the first six months of 2017 from 18.1% in the first six months of 2016. Other operating expenses is primarily comprised of contract services, professional fees, repairs and maintenance, rents and leases, utilities, insurance (including professional liability insurance) and nonincome taxes. Provisions for losses related to professional liability risks were $237 million and $223 million for the first six months of 2017 and 2016, respectively.

Equity in earnings of affiliates was $23 million and $22 million in the first six months of 2017 and 2016, respectively.

Depreciation and amortization increased $74 million, from $968 million in the first six months of 2016 to $1.042 billion in the first six months of 2017. The increase in depreciation relates primarily to increased routine capital expenditures.

Interest expense was $843 million for the first six months of 2016 and $830 million for the first six months of 2017. Our average debt balance was $31.539 billion for the first six months of 2017 compared to $30.863 billion for the first six months of 2016. The average effective interest rate for our long-term debt declined from 5.5% for the six months ended June 30, 2016 to 5.3% for the six months ended June 30, 2017.

During the first six months of 2017 and 2016, we recorded net gains on sales of facilities of $3 million and $5 million, respectively.

36

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Results of Operations (continued)

Six Months Ended June 30, 2017 and 2016 (continued)

We recorded $22 million of legal claim costs during the first six months of 2016 related to the Health Midwest litigation.

The effective tax rates were 33.2% and 31.6% for the first six months of 2017 and 2016, respectively. The effective tax rate computations exclude net income attributable to noncontrolling interests as it relates to consolidated partnerships. Our provision for income taxes for the first six months of 2017 and 2016 included tax benefits of $76 million and $118 million, respectively, related to excess tax benefits from employee equity award settlements. Our provision for income taxes for the first six months of 2017 also included $12 million of reductions in interest expense (net of tax) related to taxing authority examinations. Excluding the effect of these adjustments, the effective tax rate for the first six months of 2017 and 2016 would have been 37.7% and 37.6%, respectively.

Net income attributable to noncontrolling interests increased from $250 million for the first six months of 2016 to $256 million for the first six months of 2017.

Liquidity and Capital Resources

Cash provided by operating activities totaled $2.684 billion in the first six months of 2017 compared to $2.748 billion in the first six months of 2016. The $64 million decline in cash provided by operating activities in the first six months of 2017 compared to the first six months of 2016 related primarily to the net impact of net negative changes in working capital items of $305 million and $200 million of favorable changes in income taxes. The combined interest payments and net tax payments in the first six months of 2017 and 2016 were $1.221 billion and $1.325 billion, respectively. Working capital totaled $3.566 billion at June 30, 2017 and $3.252 billion at December 31, 2016.

Cash used in investing activities was $1.591 billion in the first six months of 2017 compared to $1.555 billion in the first six months of 2016. Acquisitions of hospitals and health care entities declined from $430 million in the first six months of 2016 to $295 million in the first six months of 2017. Excluding acquisitions, capital expenditures were $1.304 billion in the first six months of 2017 and $1.172 billion in the first six months of 2016. Capital expenditures, excluding acquisitions, are expected to approximate $2.9 billion in 2017. At June 30, 2017, there were projects under construction which had estimated additional costs to complete and equip over the next five years of approximately $3.3 billion. We expect to finance capital expenditures with internally generated and borrowed funds.

Cash used in financing activities totaled $1.034 billion in the first six months of 2017 compared to $1.243 billion in the first six months of 2016. During the first six months of 2017, net cash flows used in financing activities included a net increase of $247 million in our indebtedness, repurchases of common stock of $966 million, distributions to noncontrolling interests of $248 million and payments of debt issuance costs of $25 million. During the first six months of 2016, net cash flows used in financing activities included a net increase of $935 million in our indebtedness, repurchases of common stock of $1.858 billion, distributions to noncontrolling interests of $205 million and payments of debt issuance costs of $24 million.

We are a highly leveraged company with significant debt service requirements. Our debt totaled $31.661 billion at June 30, 2017. Our interest expense was $830 million for the first six months of 2017 and $843 million for the first six months of 2016.

In addition to cash flows from operations, available sources of capital include amounts available under our senior secured credit facilities ($3.798 billion and $2.567 billion available as of June 30, 2017 and July 31, 2017, respectively) and anticipated access to public and private debt markets.

37

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Liquidity and Capital Resources (continued)

During June 2017, we issued $1.500 billion aggregate principal amount of 5.500% senior secured notes due 2047. We will use the net proceeds for general corporate purposes, which may include funding all or a portion of the purchase price of certain previously announced hospital acquisitions, and the redemption, during the third quarter of 2017, of all $500 million aggregate principal amount of our existing 8.000% senior notes maturing in October 2018.

During June 2017, we amended our senior secured revolving credit facilities by (i) increasing the commitments under the senior secured asset-based revolving credit facility to $3.750 billion, (ii) extending the maturity date of the revolving credit commitments to June 28, 2022, (iii) amending the incremental facility provisions to permit the incurrence of additional incremental credit facilities in an aggregate principal amount of $1.5 billion and (iv) providing that the commitment fee for unutilized commitments under the senior secured asset-based revolving credit facility shall be 0.250% per annum.

During August 2016, we issued $1.200 billion aggregate principal amount of 4.500% senior secured notes due 2027. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior secured term loan using proceeds from a new $1.200 billion senior secured term loan facility maturing in February 2024.

During March 2016, we issued $1.500 billion aggregate principal amount of 5.250% senior secured notes due 2026. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior secured term loan using proceeds from a new $1.500 billion senior secured term loan facility maturing in March 2023.

Investments of our professional liability insurance subsidiaries, to maintain statutory equity and pay claims, totaled $401 million and $385 million at June 30, 2017 and December 31, 2016, respectively. An insurance subsidiary maintained net reserves for professional liability risks of $210 million and $215 million at June 30, 2017 and December 31, 2016, respectively. Our facilities are insured by a 100% owned insurance subsidiary for losses up to $50 million per occurrence; however, this coverage is subject to a $15 million per occurrence self-insured retention. Net reserves for the self-insured professional liability risks retained were $1.333 billion and $1.279 billion at June 30, 2017 and December 31, 2016, respectively. Claims payments, net of reinsurance recoveries, during the next 12 months are expected to approximate $415 million. We estimate that approximately $366 million of the expected net claim payments during the next 12 months will relate to claims subject to the self-insured retention.

Management believes that cash flows from operations, amounts available under our senior secured credit facilities and our anticipated access to public and private debt markets will be sufficient to meet expected liquidity needs during the next 12 months.

Market Risk

We are exposed to market risk related to changes in market values of securities. The investments in debt and equity securities of our 100% owned insurance subsidiaries were $398 million and $3 million, respectively, at June 30, 2017. These investments are carried at fair value, with changes in unrealized gains and losses being recorded as adjustments to other comprehensive income. At June 30, 2017, we had a net unrealized gain of $16 million on the insurance subsidiaries’ investment securities.

38

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Liquidity and Capital Resources (continued)

Market Risk (continued)

We are exposed to market risk related to market illiquidity. Investments in debt and equity securities of our 100% owned insurance subsidiaries could be impaired by the inability to access the capital markets. Should the 100% owned insurance subsidiaries require significant amounts of cash in excess of normal cash requirements to pay claims and other expenses on short notice, we may have difficulty selling these investments in a timely manner or be forced to sell them at a price less than what we might otherwise have been able to in a normal market environment. We may be required to recognize other-than-temporary impairments on our investment securities in future periods should issuers default on interest payments or should the fair market valuations of the securities deteriorate due to ratings downgrades or other issue-specific factors.

We are also exposed to market risk related to changes in interest rates, and we periodically enter into interest rate swap agreements to manage our exposure to these fluctuations. Our interest rate swap agreements involve the exchange of fixed and variable rate interest payments between two parties, based on common notional principal amounts and maturity dates. The notional amounts of the swap agreements represent balances used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions. The interest payments under these agreements are settled on a net basis. These derivatives have been recognized in the financial statements at their respective fair values. Changes in the fair value of these derivatives, which are designated as cash flow hedges, are included in other comprehensive income, and changes in the fair value of derivatives which have not been designated as hedges are recorded in operations.

With respect to our interest-bearing liabilities, approximately $2.700 billion of long-term debt at June 30, 2017 was subject to variable rates of interest, while the remaining balance in long-term debt of $28.961 billion at June 30, 2017 was subject to fixed rates of interest. Both the general level of interest rates and, for the senior secured credit facilities, our leverage affect our variable interest rates. Our variable debt is comprised primarily of amounts outstanding under the senior secured credit facilities. Borrowings under the senior secured credit facilities bear interest at a rate equal to an applicable margin plus, at our option, either (a) a base rate determined by reference to the higher of (1) the federal funds rate plus 0.50% and (2) the prime rate of Bank of America or (b) a LIBOR rate for the currency of such borrowing for the relevant interest period. The applicable margin for borrowings under the senior secured credit facilities may fluctuate according to a leverage ratio. The average effective interest rate for our long-term debt declined from 5.5% for the six months ended June 30, 2016 to 5.3% for the six months ended June 30, 2017.

The estimated fair value of our total long-term debt was $33.802 billion at June 30, 2017. The estimates of fair value are based upon the quoted market prices for the same or similar issues of long-term debt with the same maturities. Based on a hypothetical 1% increase in interest rates, the potential annualized reduction to future pretax earnings would be approximately $27 million. To mitigate the impact of fluctuations in interest rates, we generally target a portion of our debt portfolio to be maintained at fixed rates.

We are exposed to currency translation risk related to our foreign operations. Our international operations represented 2.5% of our consolidated revenues for the quarter and six months ended June 30, 2017. The United Kingdom’s vote to exit the European Union in June 2016 contributed to a 16.8% decline in the Great British pound (GBP) to US dollar (USD) translation ratio during 2016. However, the GBP/USD translation ratio has stabilized (2.5% increase) during the first six months of 2017. We currently do not consider the market risk related to GBP/USD translation to be material to our consolidated financial statements.

39

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Tax Examinations

We are subject to examination by federal, state and foreign taxing authorities. Management believes HCA Healthcare, Inc. and its predecessors, subsidiaries and affiliates properly reported taxable income and paid taxes in accordance with applicable laws and agreements established with IRS, state and foreign taxing authorities and final resolution of any disputes will not have a material, adverse effect on our results of operations or financial position. However, if payments due upon final resolution of any issues exceed our recorded estimates, such resolutions could have a material, adverse effect on our results of operations or financial position.

40

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Operating Data

	2017		2016
Number of hospitals in operation at:
March 31		171		168
June 30		172		169
September 30				169
December 31				170
Number of freestanding outpatient surgical centers in operation at:
March 31		118		116
June 30		119		116
September 30				117
December 31				118
Licensed hospital beds at(a):
March 31		44,374		43,817
June 30		44,727		44,127
September 30				44,226
December 31				44,290
Weighted average licensed beds(b):
Quarter:
First		44,362		43,780
Second		44,605		44,064
Third				44,188
Fourth				44,274
Year				44,077
Average daily census(c):
Quarter:
First		26,699		26,325
Second		25,353		25,199
Third				24,748
Fourth				25,096
Year				25,340
Admissions(d):
Quarter:
First		485,761		479,568
Second		473,174		467,218
Third				469,764
Fourth				475,281
Year				1,891,831
Equivalent admissions(e):
Quarter:
First		812,192		798,001
Second		809,367		792,599
Third				799,120
Fourth				801,799
Year				3,191,519

41

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Operating Data (continued)

	2017			2016
Average length of stay (days)(f):
Quarter:
First		4.9			5.0
Second		4.9			4.9
Third					4.8
Fourth					4.9
Emergency room visits(g):
Quarter:
First		2,163,138			2,133,289
Second		2,116,123			2,093,039
Third					2,077,938
Fourth					2,074,074
Year					8,378,340
Outpatient surgeries(h):
Quarter:
First		225,915			226,486
Second		234,215			234,578
Third					229,054
Fourth					242,095
Year					932,213
Inpatient surgeries(i):
Quarter:
First		133,341			131,840
Second		134,553			134,068
Third					135,013
Fourth					136,385
Year					537,306
Days revenues in accounts receivable(j):
Quarter:
First		48			52
Second		49			50
Third					49
Fourth					50
Outpatient revenues as a % of patient revenues(k):
Quarter:
First		37	%		38	%
Second		38	%		38	%
Third					39	%
Fourth					39	%
Year					38	%

42

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Operating Data (continued)

BALANCE SHEET DATA

	% of Accounts Receivable
	Under 91 Days			91 – 180 Days			Over 180 Days
Accounts receivable aging at June 30, 2017(l):
Medicare and Medicaid		11	%		1	%		1	%
Managed care and other discounted		29			5			6
Uninsured		21			5			21
Total		61	%		11	%		28	%

(a) Licensed beds are those beds for which a facility has been granted approval to operate from the applicable state licensing agency.

(b) Represents the average number of licensed beds, weighted based on periods owned.

(c) Represents the average number of patients in our hospital beds each day.

(d) Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume.

(e) Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and then dividing the resulting amount by gross inpatient revenues. The equivalent admissions computation “equates” outpatient revenues to the volume measure (admissions) used to measure inpatient volume resulting in a general measure of combined inpatient and outpatient volume.

(f) Represents the average number of days admitted patients stay in our hospitals.

(g) Represents the number of patients treated in our emergency rooms.

(h) Represents the number of surgeries performed on patients who were not admitted to our hospitals. Pain management and endoscopy procedures are not included in outpatient surgeries.

(i) Represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management and endoscopy procedures are not included in inpatient surgeries.

(j) Revenues per day is calculated by dividing the revenues for the quarter by the days in the quarter. Days revenues in accounts receivable is then calculated as accounts receivable, net of allowance for doubtful accounts, at the end of the quarter divided by the revenues per day. “Revenues” used in this computation are net of the provision for doubtful accounts.

(k) Represents the percentage of patient revenues related to patients who are not admitted to our hospitals.

(l) Accounts receivable aging data is based upon consolidated gross accounts receivable of $10.832 billion (each 1% is equivalent to approximately $108 million of gross accounts receivable).

43

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The information called for by this item is provided under the caption “Market Risk” under Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

ITEM 4.    CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

HCA’s chief executive officer and chief financial officer have reviewed and evaluated the effectiveness of HCA’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934) as of the end of the period covered by this quarterly report. Based on that evaluation, the chief executive officer and chief financial officer have concluded HCA’s disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity.

Health care companies are subject to numerous investigations by various governmental agencies. Further, under the federal False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material, adverse effect on our results of operations, financial position or liquidity.

ITEM 1A.    RISK FACTORS

Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this quarterly report on Form 10-Q and other risk factors described in our annual report on Form 10-K for the year ended December 31, 2016, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2016.

44

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the quarter ended June 30, 2017, we repurchased 6,404,392 shares of our common stock at an average price of $84.60 per share through market purchases pursuant to the $2 billion share repurchase program authorized during November 2016. At June 30, 2017, we had $887 million of repurchase authorization available under the November 2016 authorization.

The following table provides certain information with respect to our repurchases of common stock from April 1, 2017 through June 30, 2017 (dollars in millions, except per share amounts).

Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part  of Publicly Announced Plans or Programs		Approximate Dollar Value of Shares That May Yet  Be Purchased Under Publicly Announced Plans or Programs
April 1, 2017 through April 30, 2017		1,841,400	$	86.84		1,841,400	$	1,269
May 1, 2017 through May 31, 2017		2,287,600	$	83.48		2,287,600	$	1,078
June 1, 2017 through June 30, 2017		2,275,392	$	83.91		2,275,392	$	887
Total for second quarter 2017		6,404,392	$	84.60		6,404,392	$	887

45

ITEM 6.    EXHIBITS

(a) List of Exhibits:

4.1	—	Supplemental Indenture No. 18, dated as of June 22, 2017, among HCA Inc., HCA Healthcare, Inc., the subsidiary guarantors named therein, Delaware Trust Company, as trustee, and Deutsche Bank Trust Company Americas, as paying agent, registrar and transfer agent (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed June 22, 2017 and incorporated herein by reference).
4.2	—	Form of 5.500% Senior Secured Notes due 2047 (included in Exhibit 4.1).
4.3	—	Additional Receivables Intercreditor Agreement, dated as of June 22, 2017, by and between Bank of America, N.A., as ABL Collateral Agent, and Bank of America, N.A., as First Lien Collateral Agent (filed as Exhibit 4.7 to the Company’s Current Report on Form 8-K filed June 22, 2017 and incorporated herein by reference).
4.4	—	Restatement Agreement dated as of June 28, 2017, by and among HCA Inc., as borrower, the guarantors party thereto, Bank of America, N.A., as administrative agent and collateral agent, and the lenders party thereto (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed June 30, 2017 and incorporated herein by reference).
4.5	—	Restatement Agreement dated as of June 28, 2017, by and among HCA Inc., as borrower, the subsidiary borrowers party thereto, Bank of America, N.A., as administrative agent and collateral agent, and the lenders party thereto (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed June 30, 2017 and incorporated herein by reference).
31.1	—	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	—	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32	—	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	—	The following financial information from our quarterly report on Form 10-Q for the quarters and the six months ended June 30, 2017 and 2016, filed with the SEC on August 4, 2017, formatted in Extensible Business Reporting Language: (i) the condensed consolidated balance sheets at June 30, 2017 and December 31, 2016, (ii) the condensed consolidated income statements for the quarters and six months ended June 30, 2017 and 2016, (iii) the condensed consolidated comprehensive income statements for the quarters and six months ended June 30, 2017 and 2016, (iv) the condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016 and (v) the notes to condensed consolidated financial statements.

46

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HCA Healthcare, Inc.
By:	/S/ WILLIAM B. RUTHERFORD
	William B. Rutherford
	Executive Vice President and Chief Financial Officer

Date: August 4, 2017

47

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, R. Milton Johnson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of HCA Healthcare, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/S/ R. MILTON JOHNSON
	R. Milton Johnson
	Chairman and Chief Executive Officer

Date: August 4, 2017

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, William B. Rutherford, certify that:

1. I have reviewed this quarterly report on Form 10-Q of HCA Healthcare, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/S/ WILLIAM B. RUTHERFORD
	William B. Rutherford
	Executive Vice President and Chief Financial Officer

Date: August 4, 2017

EX-32

EXHIBIT 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of HCA Healthcare, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/S/ R. MILTON JOHNSON
	R. Milton Johnson
	Chairman and Chief Executive Officer

August 4, 2017

By:	/S/ WILLIAM B. RUTHERFORD
	William B. Rutherford
	Executive Vice President and Chief Financial Officer

August 4, 2017

XML

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	HCA
Entity Registrant Name	HCA HEALTHCARE, INC.
Entity Central Index Key	0000860730
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		361,249,700

XML

Condensed Consolidated Income Statements (Unaudited) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenues before provision for doubtful accounts	$ 11,806	$ 11,081	$ 23,189	$ 22,131
Provision for doubtful accounts	1,073	762	1,833	1,552
Revenues	10,733	10,319	21,356	20,579
Salaries and benefits	4,896	4,691	9,797	9,393
Supplies	1,795	1,718	3,592	3,432
Other operating expenses	1,965	1,868	3,895	3,721
Equity in earnings of affiliates	(13)	(10)	(23)	(22)
Depreciation and amortization	521	489	1,042	968
Interest expense	411	427	830	843
Gains on sales of facilities	(2)	(6)	(3)	(5)
Legal claim costs		10		22
Total expenses including equity in earnings of affiliates	9,573	9,187	19,130	18,352
Income before income taxes	1,160	1,132	2,226	2,227
Provision for income taxes	365	341	654	625
Net income	795	791	1,572	1,602
Net income attributable to noncontrolling interests	138	133	256	250
Net income attributable to HCA Healthcare, Inc.	$ 657	$ 658	$ 1,316	$ 1,352
Per share data:
Basic earnings per share	$ 1.79	$ 1.70	$ 3.58	$ 3.45
Diluted earnings per share	$ 1.75	$ 1.65	$ 3.48	$ 3.34
Shares used in earnings per share calculations (in millions):
Basic	365,847	386,406	368,056	391,401
Diluted	375,338	398,659	377,647	404,617

XML

Condensed Consolidated Comprehensive Income Statements (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 795	$ 791	$ 1,572	$ 1,602
Other comprehensive income (loss) before taxes:
Foreign currency translation	45	(86)	55	(129)
Unrealized gains on available-for-sale securities	2	3	5	5
Defined benefit plans	0	0	0	0
Pension costs included in salaries and benefits	4	5	9	9
Total defined benefit plans	4	5	9	9
Change in fair value of derivative financial instruments	(11)	(32)	(8)	(70)
Interest costs included in interest expense	6	28	13	56
Total change in fair value of derivative financial instruments	(5)	(4)	5	(14)
Other comprehensive income (loss) before taxes	46	(82)	74	(129)
Income taxes (benefits) related to other comprehensive income items	19	(32)	29	(50)
Other comprehensive income (loss)	27	(50)	45	(79)
Comprehensive income	822	741	1,617	1,523
Comprehensive income attributable to noncontrolling interests	138	133	256	250
Comprehensive income attributable to HCA Healthcare, Inc.	$ 684	$ 608	$ 1,361	$ 1,273

XML

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 705	$ 646
Accounts receivable, less allowance for doubtful accounts of $5,050 and $4,988	5,782	5,826
Inventories	1,544	1,503
Other	1,306	1,111
Total current assets	9,337	9,086
Property and equipment, at cost	38,306	37,055
Accumulated depreciation	(21,538)	(20,703)
Property and equipment, net	16,768	16,352
Investments of insurance subsidiaries	352	336
Investments in and advances to affiliates	197	206
Goodwill and other intangible assets	6,771	6,704
Other	1,141	1,074
Total assets	34,566	33,758
Current liabilities:
Accounts payable	2,245	2,318
Accrued salaries	1,209	1,265
Other accrued expenses	2,104	2,035
Long-term debt due within one year	213	216
Total current liabilities	5,771	5,834
Long-term debt, less net debt issuance costs of $179 and $170	31,448	31,160
Professional liability risks	1,144	1,148
Income taxes and other liabilities	1,282	1,249
Stockholders' deficit:
Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 362,895,000 shares in 2017 and 370,535,900 shares in 2016	4	4
Accumulated other comprehensive loss	(293)	(338)
Retained deficit	(6,503)	(6,968)
Stockholders' deficit attributable to HCA Healthcare, Inc.	(6,792)	(7,302)
Noncontrolling interests	1,713	1,669
Total stockholders' deficit	(5,079)	(5,633)
Total liabilities and stockholders' deficit	$ 34,566	$ 33,758

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for Accounts receivable	$ 5,050	$ 4,988
Debt issuance cost	$ 179	$ 170
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	1,800,000,000	1,800,000,000
Common stock, shares outstanding	362,895,000	370,535,900

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income	$ 1,572	$ 1,602
Increase (decrease) in cash from operating assets and liabilities:
Accounts receivable	(1,752)	(1,364)
Provision for doubtful accounts	1,833	1,552
Accounts receivable, net	81	188
Inventories and other assets	(178)	(176)
Accounts payable and accrued expenses	(298)	(102)
Depreciation and amortization	1,042	968
Income taxes	267	67
Gains on sales of facilities	(3)	(5)
Legal claim costs		22
Amortization of debt issuance costs	16	18
Share-based compensation	140	129
Other	45	37
Net cash provided by (used in) operating activities	2,684	2,748
Cash flows from investing activities:
Purchase of property and equipment	(1,304)	(1,172)
Acquisition of hospitals and health care entities	(295)	(430)
Disposal of hospitals and health care entities	14	14
Change in investments	(11)	18
Other	5	15
Net cash used in investing activities	(1,591)	(1,555)
Cash flows from financing activities:
Issuances of long-term debt	1,502	3,000
Net change in revolving bank credit facilities	(1,160)
Repayment of long-term debt	(95)	(2,065)
Distributions to noncontrolling interests	(248)	(205)
Payment of debt issuance costs	(25)	(24)
Repurchases of common stock	(966)	(1,858)
Other	(42)	(91)
Net cash (used in) provided by financing activities	(1,034)	(1,243)
Change in cash and cash equivalents	59	(50)
Cash and cash equivalents at beginning of period	646	741
Cash and cash equivalents at end of period	705	691
Interest payments	834	767
Income tax payments, net	$ 387	$ 558

XML

Basis of Presentation and Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Reporting Entity

HCA Healthcare, Inc. (formerly known as HCA Holdings, Inc.) is a holding company whose affiliates own and operate hospitals and related health care entities. The term “affiliates” includes direct and indirect subsidiaries of HCA Healthcare, Inc. and partnerships and joint ventures in which such subsidiaries are partners. At June 30, 2017, these affiliates owned and operated 172 hospitals, 119 freestanding surgery centers and provided extensive outpatient and ancillary services. HCA Healthcare, Inc.’s facilities are located in 20 states and England. The terms “Company,” “HCA,” “we,” “our” or “us,” as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of HCA and the term “employees” refers to employees of affiliates of HCA.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature.

The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $92 million and $93 million for the quarters ended June 30, 2017 and 2016, respectively, and $182 million and $178 million for the six months ended June 30, 2017 and 2016, respectively. Operating results for the quarter and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2016.

Revenues

Revenues are recorded during the period the health care services are provided, based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans and commercial insurance companies (including plans offered through the health insurance exchanges), and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record a provision for doubtful accounts (based primarily on historical collection experience) related to uninsured accounts to record net self-pay revenues at the estimated amounts we expect to collect. Our revenues from third-party payers, the uninsured and other for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter
	2017			Ratio			2016			Ratio
Medicare	$	2,321			21.6	%	$	2,217			21.5	%
Managed Medicare		1,187			11.1			1,078			10.4
Medicaid		453			4.2			416			4.0
Managed Medicaid		575			5.4			608			5.9
Managed care and other insurers		6,106			56.9			5,759			55.8
International (managed care and other insurers)		269			2.5			324			3.1
		10,911			101.7			10,402			100.7
Uninsured		519			4.8			225			2.2
Other		376			3.5			454			4.4
Revenues before provision for doubtful accounts		11,806			110.0			11,081			107.3
Provision for doubtful accounts		(1,073	)		(10.0	)		(762	)		(7.3	)
Revenues	$	10,733			100.0	%	$	10,319			100.0	%

	Six Months
	2017			Ratio			2016			Ratio
Medicare	$	4,726			22.1	%	$	4,483			21.8	%
Managed Medicare		2,390			11.2			2,182			10.6
Medicaid		826			3.9			843			4.1
Managed Medicaid		1,216			5.7			1,205			5.9
Managed care and other insurers		12,032			56.3			11,461			55.7
International (managed care and other insurers)		538			2.5			641			3.1
		21,728			101.7			20,815			101.2
Uninsured		744			3.5			414			2.0
Other		717			3.4			902			4.4
Revenues before provision for doubtful accounts		23,189			108.6			22,131			107.6
Provision for doubtful accounts		(1,833	)		(8.6	)		(1,552	)		(7.6	)
Revenues	$	21,356			100.0	%	$	20,579			100.0	%

Recent Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) and the International Accounting Standards Board issued a final, converged, principles-based standard on revenue recognition. Companies across all industries will use a five-step model to recognize revenue from customer contracts. The new standard, which replaces nearly all existing revenue recognition guidance, will require significant management judgments and change the way many companies recognize revenue in their financial statements. In July 2015, the FASB decided to defer the effective date of the new revenue standard by one year to annual and interim periods beginning after December 15, 2017 for public entities and permit entities to adopt one year earlier if they choose. The FASB decided, based on its outreach to various stakeholders and continuing amendments to the new revenue standard, that a deferral was necessary to provide adequate time to effectively implement the new standard. We are continuing to evaluate the effects the adoption of this standard will have on our financial statements and financial disclosures. We believe the most significant impact will be to the presentation of our income statement where the provision for doubtful accounts will be recorded as a direct reduction to revenues and will not be presented as a separate line item. We expect to adopt the new standard using the full retrospective application, and we do not currently believe the adoption will have a significant impact on our recognition of net revenues or related disclosures for any period.

In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for most leases. ASU 2016-02 is effective for public business entities for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. ASU 2016-02’s transition provisions will be applied using a modified retrospective approach at the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the provisions of ASU 2016-02 to determine how our financial statements will be affected, and we believe the primary effect of adopting the new standard will be to record right-of-use assets and obligations for our leases currently classified as operating leases.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

XML

Acquisitions and Dispositions

6 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

Acquisitions and Dispositions

NOTE 2 — ACQUISITIONS AND DISPOSITIONS

During the six months ended June 30, 2017, we paid $189 million to acquire three hospital facilities (two of the hospital facilities have effective acquisition dates of July 1, 2017) and $106 million to acquire other nonhospital health care entities. During the six months ended June 30, 2016, we paid $343 million to acquire three hospital facilities and $87 million to acquire other nonhospital health care entities.

During the six months ended June 30, 2017, we received proceeds of $14 million and recognized a net pretax gain of $3 million related to sales of real estate and other investments. During the six months ended June 30, 2016, we received proceeds of $14 million and recognized a net pretax gain of $5 million related to sales of real estate and other investments.

XML

Income Taxes

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 3 — INCOME TAXES

Our liability for unrecognized tax benefits was $420 million, including accrued interest of $46 million, as of June 30, 2017 ($418 million and $45 million, respectively, as of December 31, 2016). Unrecognized tax benefits of $141 million ($137 million as of December 31, 2016) would affect the effective rate, if recognized.

Our provision for income taxes for the quarters ended June 30, 2017 and 2016, included tax benefits of $9 million and $44 million, respectively, and for the six months ended June 30, 2017 and 2016, included tax benefits of $76 million and $118 million, respectively, related to the settlement of employee equity awards. Our provision for income taxes for the quarter and six months ended June 30, 2017 also included $10 million and $12 million, respectively, of reductions in interest expense (net of tax) related to taxing authority examinations.

We are subject to examination by federal, state and foreign taxing authorities. Depending on the resolution of any federal, state and foreign tax disputes, the completion of examinations by federal, state or foreign taxing authorities, or the expiration of statutes of limitation for specific taxing jurisdictions, we believe it is reasonably possible that our liability for unrecognized tax benefits may significantly increase or decrease within the next 12 months. However, we are currently unable to estimate the range of any possible change.

XML

Earnings Per Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share

NOTE 4 — EARNINGS PER SHARE

We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards and potential shares, computed using the treasury stock method.

The following table sets forth the computation of basic and diluted earnings per share for the quarters and six months ended June 30, 2017 and 2016 (dollars and shares in millions, except per share amounts):

	Quarter				Six Months
	2017		2016		2017		2016
Net income attributable to HCA Healthcare, Inc.	$	657	$	658	$	1,316	$	1,352
Weighted average common shares outstanding		365.847		386.406		368.056		391.401
Effect of dilutive incremental shares		9.491		12.253		9.591		13.216
Shares used for diluted earnings per share		375.338		398.659		377.647		404.617
Earnings per share:
Basic earnings per share	$	1.79	$	1.70	$	3.58	$	3.45
Diluted earnings per share	$	1.75	$	1.65	$	3.48	$	3.34

XML

Investments of Insurance Subsidiaries

6 Months Ended

Jun. 30, 2017

Investments, Debt and Equity Securities [Abstract]

Investments of Insurance Subsidiaries

NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES

A summary of our insurance subsidiaries’ investments at June 30, 2017 and December 31, 2016 follows (dollars in millions):

	June 30, 2017
	Amortized Cost		Unrealized Amounts				Fair Value
			Gains		Losses
Debt securities:
States and municipalities	$	364		$14		$—	$	378
Money market funds		20		—		—		20
		384		14		—		398
Equity securities		1		2		—		3
	$	385		$16		$—		401
Amounts classified as current assets								(49	)
Investment carrying value							$	352

	December 31, 2016
	Amortized Cost		Unrealized Amounts				Fair Value
			Gains		Losses
Debt securities:
States and municipalities	$	345		$9		$(1)	$	353
Money market funds		28		—		—		28
		373		9		(1)		381
Equity securities		1		3		—		4
	$	374		$12		$(1)		385
Amounts classified as current assets								(49	)
Investment carrying value							$	336

At June 30, 2017 and December 31, 2016, the investments of our insurance subsidiaries were classified as “available-for-sale.” Changes in temporary unrealized gains and losses are recorded as adjustments to other comprehensive income (loss).

Scheduled maturities of investments in debt securities at June 30, 2017 were as follows (dollars in millions):

	Amortized Cost		Fair Value
Due in one year or less	$	96	$	96
Due after one year through five years		71		74
Due after five years through ten years		174		184
Due after ten years		43		44
	$	384	$	398

The average expected maturity of the investments in debt securities at June 30, 2017 was 3.9 years, compared to the average scheduled maturity of 5.5 years. Expected and scheduled maturities may differ because the issuers of certain securities have the right to call, prepay or otherwise redeem such obligations prior to their scheduled maturity date.

XML

Financial Instruments

6 Months Ended

Jun. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments

NOTE 6 — FINANCIAL INSTRUMENTS

Interest Rate Swap Agreements

We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between two parties based on common notional principal amounts and maturity dates. Pay-fixed interest rate swaps effectively convert LIBOR indexed variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions.

The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at June 30, 2017 (dollars in millions):

	Notional Amount		Maturity Date		Fair Value
Pay-fixed interest rate swaps	$	1,000		December 2017	$	(5	)
Pay-fixed interest rate swaps		2,000		December 2021		29

During the next 12 months, we estimate $8 million will be reclassified from other comprehensive income (“OCI”) to interest expense.

Derivatives — Results of Operations

The following table presents the effect of our interest rate swaps on our results of operations for the six months ended June 30, 2017 (dollars in millions):

Derivatives in Cash Flow Hedging Relationships	Amount of Loss Recognized in OCI on Derivatives, Net of  Tax		Location of Loss Reclassified from Accumulated OCI into Operations		Amount of Loss Reclassified from Accumulated OCI into Operations
Interest rate swaps	$	5		Interest expense	$	13

XML

Assets and Liabilities Measured at Fair Value

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value

NOTE 7 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC 820”) emphasizes fair value is a market-based measurement, and fair value measurements should be determined based on the assumptions market participants would use in pricing assets or liabilities. ASC 820 utilizes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment.

Cash Traded Investments

Our cash traded investments are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Certain types of cash traded instruments are classified within Level 3 of the fair value hierarchy because they trade infrequently and therefore have little or no price transparency. The valuation of these securities involves the consideration of market factors and management’s judgment.

Derivative Financial Instruments

We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments.

Although we determined the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with our derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. We assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative positions, and at June 30, 2017 and December 31, 2016, we determined the credit valuation adjustments were not significant to the overall valuation of our derivatives.

The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions):

	June 30, 2017
				Fair Value Measurements Using
	Fair Value			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Assets:
Investments of insurance subsidiaries:
Debt securities:
States and municipalities	$	378		$	—		$	378		$	—
Money market funds		20			20			—			—
		398			20			378			—
Equity securities		3			3			—			—
Investments of insurance subsidiaries		401			23			378			—
Less amounts classified as current assets		(49	)		(20	)		(29	)		—
	$	352		$	3		$	349		$	—
Interest rate swaps (Other)	$	29		$	—		$	29		$	—
Liabilities:
Interest rate swaps (Income taxes and other liabilities)	$	5		$	—		$	5		$	—
	December 31, 2016
				Fair Value Measurements Using
	Fair Value			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Assets:
Investments of insurance subsidiaries:
Debt securities:
States and municipalities	$	353		$	—		$	347		$	6
Money market funds		28			28			—			—
		381			28			347			6
Equity securities		4			4			—			—
Investments of insurance subsidiaries		385			32			347			6
Less amounts classified as current assets		(49	)		(28	)		(21	)		—
	$	336		$	4		$	326		$	6
Interest rate swaps (Other)	$	31		$	—		$	31		$	—
Liabilities:
Interest rate swaps (Income taxes and other liabilities)	$	12		$	—		$	12		$	—

The $6 million reduction in the Level 3 investments of our insurance subsidiaries resulted from settlements. The estimated fair value of our long-term debt was $33.802 billion and $32.833 billion at June 30, 2017 and December 31, 2016, respectively, compared to carrying amounts, excluding net debt issuance costs, aggregating $31.840 billion and $31.546 billion, respectively. The estimates of fair value are generally based upon the quoted market prices or quoted market prices for similar issues of long-term debt with the same maturities.

XML

Long-Term Debt

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Long-Term Debt

NOTE 8 — LONG-TERM DEBT

A summary of long-term debt at June 30, 2017 and December 31, 2016, including related interest rates at June 30, 2017, follows (dollars in millions):

	June 30, 2017			December 31, 2016
Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)	$	1,760		$	2,920
Senior secured revolving credit facility		—			—
Senior secured term loan facilities (effective interest rate of 3.6%)		3,939			3,981
Senior secured notes (effective interest rate of 5.4%)		15,300			13,800
Other senior secured debt (effective interest rate of 5.8%)		589			593
Senior secured debt		21,588			21,294
Senior unsecured notes (effective interest rate of 6.5%)		10,252			10,252
Net debt issuance costs		(179	)		(170	)
Total debt (average life of 7.3 years, rates averaging 5.4%)		31,661			31,376
Less amounts due within one year		213			216
	$	31,448		$	31,160

2017 Activity

During June 2017, we issued $1.500 billion aggregate principal amount of 5.500% senior secured notes due 2047. We will use the net proceeds for general corporate purposes, which may include funding all or a portion of the purchase price of certain previously announced hospital acquisitions, and the redemption, during the third quarter of 2017, of all $500 million aggregate principal amount of our existing 8.000% senior notes maturing in October 2018.

During June 2017, we amended our senior secured revolving credit facilities by (i) increasing the commitments under the senior secured asset-based revolving credit facility to $3.750 billion, (ii) extending the maturity date of the revolving credit commitments to June 28, 2022, (iii) amending the incremental facility provisions to permit the incurrence of additional incremental credit facilities in an aggregate principal amount of $1.5 billion and (iv) providing that the commitment fee for unutilized commitments under the senior secured asset-based revolving credit facility shall be 0.250% per annum.

2016 Activity

During August 2016, we issued $1.200 billion aggregate principal amount of 4.500% senior secured notes due 2027. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior secured term loan using proceeds from a new $1.200 billion senior secured term loan facility maturing in February 2024.

During March 2016, we issued $1.500 billion aggregate principal amount of 5.250% senior secured notes due 2026. We used the net proceeds for general corporate purposes and to retire a portion of one of our senior secured term loans. We also entered into a joinder agreement to retire the remaining portion of this senior secured term loan using proceeds from a new $1.500 billion senior secured term loan facility maturing in March 2023.

XML

Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Contingencies

NOTE 9 — CONTINGENCIES

We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity.

Health care companies are subject to numerous investigations by various governmental agencies. Under the federal False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material, adverse effect on our results of operations, financial position or liquidity.

XML

Capital Structure

6 Months Ended

Jun. 30, 2017

Text Block [Abstract]

Capital Structure

NOTE 10 — CAPITAL STRUCTURE

The changes in stockholders’ deficit, including changes in stockholders’ deficit attributable to HCA Healthcare, Inc. and changes in equity attributable to noncontrolling interests, are as follows (dollars and shares in millions):

	Equity (Deficit) Attributable to HCA Healthcare, Inc.														Equity Attributable to Noncontrolling Interests			Total
	Common Stock					Capital in Excess of Par Value			Accumulated Other Comprehensive Loss			Retained Deficit
	Shares			Par Value
Balances at December 31, 2016		370.536		$	4	$	—		$	(338	)	$	(6,968	)	$	1,669		$	(5,633	)
Comprehensive income		—			—		—			45			1,316			256			1,617
Repurchase of common stock		(11.525	)		—		(115	)		—			(851	)		—			(966	)
Distributions		—			—		—			—			—			(248	)		(248	)
Share-based benefit plans		3.884			—		117			—			—			—			117
Other		—			—		(2	)		—			—			36			34
Balances at June 30, 2017		362.895		$	4	$	—		$	(293	)	$	(6,503	)	$	1,713		$	(5,079	)

During the six months ended June 30, 2017, we repurchased 11.525 million shares of our common stock at an average price of $83.81 per share through market purchases pursuant to the $2.0 billion share repurchase program authorized during November 2016. At June 30, 2017, we had $887 million of repurchase authorization available under the November 2016 authorization.

The components of accumulated other comprehensive loss are as follows (dollars in millions):

	Unrealized Gains on Available- for-Sale Securities		Foreign Currency Translation Adjustments			Defined Benefit Plans			Change in Fair Value of Derivative Instruments			Total
Balances at December 31, 2016	$	7	$	(211	)	$	(146	)	$	12		$	(338	)
Unrealized gains on available-for-sale securities, net of $2 of income taxes		3		—			—			—			3
Foreign currency translation adjustments, net of $22 of income taxes		—		33			—			—			33
Change in fair value of derivative instruments, net of $3 income tax benefits		—		—			—			(5	)		(5	)
Expense reclassified into operations from other comprehensive income, net of $3 and $5, respectively, income tax benefits		—		—			6			8			14
Balances at June 30, 2017	$	10	$	(178	)	$	(140	)	$	15		$	(293	)

XML

Segment and Geographic Information

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Segment and Geographic Information

NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION

We operate in one line of business, which is operating hospitals and related health care entities. We operate in two geographically organized groups: the National and American Groups. The National Group includes 86 hospitals located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia, and the American Group includes 80 hospitals located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. We also operate six hospitals in England, and these facilities are included in the Corporate and other group.

Adjusted segment EBITDA is defined as income before depreciation and amortization, interest expense, gains on sales of facilities, legal claim costs, income taxes and net income attributable to noncontrolling interests. We use adjusted segment EBITDA as an analytical indicator for purposes of allocating resources to geographic areas and assessing their performance. Adjusted segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from adjusted segment EBITDA are significant components in understanding and assessing financial performance. Because adjusted segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter						Six Months
	2017			2016			2017			2016
Revenues:
National Group	$	5,160		$	4,931		$	10,308		$	9,898
American Group		5,093			4,860			10,088			9,646
Corporate and other		480			528			960			1,035
	$	10,733		$	10,319		$	21,356		$	20,579
Equity in earnings of affiliates:
National Group	$	(4	)	$	(2	)	$	(9	)	$	(4	)
American Group		(10	)		(8	)		(18	)		(17	)
Corporate and other		1			—			4			(1	)
	$	(13	)	$	(10	)	$	(23	)	$	(22	)
Adjusted segment EBITDA:
National Group	$	1,162		$	1,131		$	2,293		$	2,269
American Group		1,040			1,004			2,047			1,986
Corporate and other		(112	)		(83	)		(245	)		(200	)
	$	2,090		$	2,052		$	4,095		$	4,055
Depreciation and amortization:
National Group	$	217		$	201		$	431		$	398
American Group		238			225			476			444
Corporate and other		66			63			135			126
	$	521		$	489		$	1,042		$	968
Adjusted segment EBITDA	$	2,090		$	2,052		$	4,095		$	4,055
Depreciation and amortization		521			489			1,042			968
Interest expense		411			427			830			843
Gains on sales of facilities		(2	)		(6	)		(3	)		(5	)
Legal claim costs		—			10			—			22
Income before income taxes	$	1,160		$	1,132		$	2,226		$	2,227

XML

Supplemental Condensed Consolidating Financial Information

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Condensed Consolidating Financial Information

NOTE 12 — SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

During December 2012, HCA Healthcare, Inc. issued $1.000 billion aggregate principal amount of 6.250% senior unsecured notes due 2021. These notes are senior unsecured obligations and are not guaranteed by any of our subsidiaries.

HCA Inc., a direct wholly-owned subsidiary of HCA Healthcare, Inc., is the obligor under a significant portion of our other indebtedness, including our senior secured credit facilities, senior secured notes and senior unsecured notes (other than the senior unsecured notes issued by HCA Healthcare, Inc.). The senior secured notes and senior unsecured notes issued by HCA Inc. are fully and unconditionally guaranteed by HCA Healthcare, Inc. The senior secured credit facilities and senior secured notes are fully and unconditionally guaranteed by substantially all existing and future, direct and indirect, 100% owned material domestic subsidiaries that are “Unrestricted Subsidiaries” under our Indenture dated December 16, 1993 (except for certain special purpose subsidiaries that only guarantee and pledge their assets under our senior secured asset-based revolving credit facility).

Our summarized condensed consolidating comprehensive income statements for the quarters and six months ended June 30, 2017 and 2016, condensed consolidating balance sheets at June 30, 2017 and December 31, 2016 and condensed consolidating statements of cash flows for the six months ended June 30, 2017 and 2016, segregating HCA Healthcare, Inc. issuer, HCA Inc. issuer, the subsidiary guarantors, the subsidiary non-guarantors and eliminations, follow:

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE QUARTER ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	6,049		$	5,757		$	—		$	11,806
Provision for doubtful accounts		—			—			593			480			—			1,073
Revenues		—			—			5,456			5,277			—			10,733
Salaries and benefits		—			—			2,437			2,459			—			4,896
Supplies		—			—			931			864			—			1,795
Other operating expenses		4			—			951			1,010			—			1,965
Equity in earnings of affiliates		(658	)		—			(1	)		(12	)		658			(13	)
Depreciation and amortization		—			—			248			273			—			521
Interest expense		16			755			(291	)		(69	)		—			411
Gains on sales of facilities		—			—			(1	)		(1	)		—			(2	)
Management fees		—			—			(212	)		212			—			—
		(638	)		755			4,062			4,736			658			9,573
Income (loss) before income taxes		638			(755	)		1,394			541			(658	)		1,160
Provision (benefit) for income taxes		(19	)		(279	)		505			158			—			365
Net income (loss)		657			(476	)		889			383			(658	)		795
Net income attributable to noncontrolling interests		—			—			27			111			—			138
Net income (loss) attributable to HCA Healthcare, Inc.	$	657		$	(476	)	$	862		$	272		$	(658	)	$	657
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	684		$	(480	)	$	865		$	300		$	(685	)	$	684

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE QUARTER ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	5,693		$	5,388		$	—		$	11,081
Provision for doubtful accounts		—			—			498			264			—			762
Revenues		—			—			5,195			5,124			—			10,319
Salaries and benefits		—			—			2,347			2,344			—			4,691
Supplies		—			—			886			832			—			1,718
Other operating expenses		2			—			893			973			—			1,868
Equity in earnings of affiliates		(641	)		—			(1	)		(9	)		641			(10	)
Depreciation and amortization		—			—			238			251			—			489
Interest expense		16			670			(204	)		(55	)		—			427
Gains on sales of facilities		—			—			(2	)		(4	)		—			(6	)
Legal claim costs		—			10			—			—			—			10
Management fees		—			—			(235	)		235			—			—
		(623	)		680			3,922			4,567			641			9,187
Income (loss) before income taxes		623			(680	)		1,273			557			(641	)		1,132
Provision (benefit) for income taxes		(35	)		(251	)		462			165			—			341
Net income (loss)		658			(429	)		811			392			(641	)		791
Net income attributable to noncontrolling interests		—			—			21			112			—			133
Net income (loss) attributable to HCA Healthcare, Inc.	$	658		$	(429	)	$	790		$	280		$	(641	)	$	658
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	608		$	(431	)	$	794		$	228		$	(591	)	$	608

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	11,902		$	11,287		$	—		$	23,189
Provision for doubtful accounts		—			—			1,012			821			—			1,833
Revenues		—			—			10,890			10,466			—			21,356
Salaries and benefits		—			—			4,903			4,894			—			9,797
Supplies		—			—			1,882			1,710			—			3,592
Other operating expenses		5			—			1,878			2,012			—			3,895
Equity in earnings of affiliates		(1,266	)		—			(2	)		(21	)		1,266			(23	)
Depreciation and amortization		—			—			499			543			—			1,042
Interest expense		32			1,488			(560	)		(130	)		—			830
Gains on sales of facilities		—			—			(1	)		(2	)		—			(3	)
Management fees		—			—			(422	)		422			—			—
		(1,229	)		1,488			8,177			9,428			1,266			19,130
Income (loss) before income taxes		1,229			(1,488	)		2,713			1,038			(1,266	)		2,226
Provision (benefit) for income taxes		(87	)		(549	)		983			307			—			654
Net income (loss)		1,316			(939	)		1,730			731			(1,266	)		1,572
Net income attributable to noncontrolling interests		—			—			50			206			—			256
Net income (loss) attributable to HCA Healthcare, Inc.	$	1,316		$	(939	)	$	1,680		$	525		$	(1,266	)	$	1,316
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	1,361		$	(936	)	$	1,686		$	561		$	(1,311	)	$	1,361

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	11,366		$	10,765		$	—		$	22,131
Provision for doubtful accounts		—			—			992			560			—			1,552
Revenues		—			—			10,374			10,205			—			20,579
Salaries and benefits		—			—			4,701			4,692			—			9,393
Supplies		—			—			1,784			1,648			—			3,432
Other operating expenses		4			—			1,750			1,967			—			3,721
Equity in earnings of affiliates		(1,270	)		—			(3	)		(19	)		1,270			(22	)
Depreciation and amortization		—			—			465			503			—			968
Interest expense		32			1,320			(411	)		(98	)		—			843
Gains on sales of facilities		—			—			—			(5	)		—			(5	)
Legal claim costs		—			22			—			—			—			22
Management fees		—			—			(395	)		395			—			—
		(1,234	)		1,342			7,891			9,083			1,270			18,352
Income (loss) before income taxes		1,234			(1,342	)		2,483			1,122			(1,270	)		2,227
Provision (benefit) for income taxes		(118	)		(495	)		900			338			—			625
Net income (loss)		1,352			(847	)		1,583			784			(1,270	)		1,602
Net income attributable to noncontrolling interests		—			—			43			207			—			250
Net income (loss) attributable to HCA Healthcare, Inc.	$	1,352		$	(847	)	$	1,540		$	577		$	(1,270	)	$	1,352
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	1,273		$	(856	)	$	1,546		$	501		$	(1,191	)	$	1,273

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING BALANCE SHEET

JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors		Eliminations			Condensed Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—		$	—		$	155		$	550	$	—		$	705
Accounts receivable, net		—			—			2,991			2,791		—			5,782
Inventories		—			—			923			621		—			1,544
Other		—			—			522			784		—			1,306
		—			—			4,591			4,746		—			9,337
Property and equipment, net		—			—			8,560			8,208		—			16,768
Investments of insurance subsidiaries		—			—			—			352		—			352
Investments in and advances to affiliates		28,356			—			15			182		(28,356	)		197
Goodwill and other intangible assets		—			—			1,727			5,044		—			6,771
Other		805			29			33			274		—			1,141
	$	29,161		$	29		$	14,926		$	18,806	$	(28,356	)	$	34,566
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	—		$	—		$	1,342		$	903	$	—		$	2,245
Accrued salaries		—			—			679			530		—			1,209
Other accrued expenses		281			383			457			983		—			2,104
Long-term debt due within one year		—			97			57			59		—			213
		281			480			2,535			2,475		—			5,771
Long-term debt, net		994			29,981			188			285		—			31,448
Intercompany balances		34,258			(9,404	)		(27,765	)		2,911		—			—
Professional liability risks		—			—			—			1,144		—			1,144
Income taxes and other liabilities		420			5			403			454		—			1,282
		35,953			21,062			(24,639)			7,269		—			39,645
Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc.		(6,792	)		(21,033	)		39,438			9,951		(28,356	)		(6,792	)
Noncontrolling interests		—			—			127			1,586		—			1,713
		(6,792	)		(21,033	)		39,565			11,537		(28,356	)		(5,079	)
	$	29,161		$	29		$	14,926		$	18,806	$	(28,356	)	$	34,566

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING BALANCE SHEET

DECEMBER 31, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors		Eliminations			Condensed Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—		$	—		$	110		$	536	$	—		$	646
Accounts receivable, net		—			—			3,028			2,798		—			5,826
Inventories		—			—			890			613		—			1,503
Other		—			—			445			666		—			1,111
		—			—			4,473			4,613		—			9,086
Property and equipment, net		—			—			8,463			7,889		—			16,352
Investments of insurance subsidiaries		—			—			—			336		—			336
Investments in and advances to affiliates		27,045			—			16			190		(27,045	)		206
Goodwill and other intangible assets		—			—			1,728			4,976		—			6,704
Other		877			—			34			163		—			1,074
	$	27,922		$	—		$	14,714		$	18,167	$	(27,045	)	$	33,758
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	—		$	—		$	1,439		$	879	$	—		$	2,318
Accrued salaries		—			—			704			561		—			1,265
Other accrued expenses		29			572			464			970		—			2,035
Long-term debt due within one year		—			97			60			59		—			216
		29			669			2,667			2,469		—			5,834
Long-term debt, net		993			29,693			199			275		—			31,160
Intercompany balances		33,784			(10,277	)		(26,447	)		2,940		—			—
Professional liability risks		—			—			—			1,148		—			1,148
Income taxes and other liabilities		418			12			387			432		—			1,249
		35,224			20,097			(23,194	)		7,264		—			39,391
Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc.		(7,302	)		(20,097	)		37,752			9,390		(27,045	)		(7,302	)
Noncontrolling interests		—			—			156			1,513		—			1,669
		(7,302	)		(20,097	)		37,908			10,903		(27,045	)		(5,633	)
	$	27,922		$	—		$	14,714		$	18,167	$	(27,045	)	$	33,758

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Cash flows from operating activities:
Net income (loss)	$	1,316		$	(939	)	$	1,730		$	731		$	(1,266	)	$	1,572
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities		1			(189	)		(1,189	)		(851	)		—			(2,228	)
Provision for doubtful accounts		—			—			1,012			821			—			1,833
Depreciation and amortization		—			—			499			543			—			1,042
Income taxes		267			—			—			—			—			267
Gains on sales of facilities		—			—			(1	)		(2	)		—			(3	)
Amortization of debt issuance costs		—			16			—			—			—			16
Share-based compensation		—			—			140			—			—			140
Equity in earnings of affiliates		(1,266	)		—			—			—			1,266			—
Other		39			—			—			6			—			45
Net cash provided by (used in) operating activities		357			(1,112	)		2,191			1,248			—			2,684
Cash flows from investing activities:
Purchase of property and equipment		—			—			(578	)		(726	)		—			(1,304	)
Acquisition of hospitals and health care entities		—			—			(5	)		(290	)		—			(295	)
Disposition of hospitals and health care entities		—			—			10			4			—			14
Change in investments		—			—			—			(11	)		—			(11	)
Other		—			—			2			3			—			5
Net cash used in investing activities		—			—			(571	)		(1,020	)		—			(1,591	)
Cash flows from financing activities:
Issuance of long-term debt		—			1,500			—			2			—			1,502
Net change in revolving credit facilities		—			(1,160	)		—			—			—			(1,160	)
Repayment of long-term debt		—			(42	)		(33	)		(20	)		—			(95	)
Distributions to noncontrolling interests		—			—			(79	)		(169	)		—			(248	)
Payment of debt issuance costs		—			(25	)		—			—			—			(25	)
Repurchases of common stock		(966	)		—			—			—			—			(966	)
Changes in intercompany balances with affiliates, net		671			839			(1,463	)		(47	)		—			—
Other		(62	)		—			—			20			—			(42	)
Net cash (used in) provided by financing activities		(357	)		1,112			(1,575	)		(214	)		—			(1,034	)
Change in cash and cash equivalents		—			—			45			14			—			59
Cash and cash equivalents at beginning of period		—			—			110			536			—			646
Cash and cash equivalents at end of period	$	—		$	—		$	155		$	550		$	—		$	705

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Cash flows from operating activities:
Net income (loss)	$	1,352		$	(847	)	$	1,583		$	784		$	(1,270	)	$	1,602
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities		(23	)		66			(1,140	)		(545	)		—			(1,642	)
Provision for doubtful accounts		—			—			992			560			—			1,552
Depreciation and amortization		—			—			465			503			—			968
Income taxes		67			—			—			—			—			67
Gains on sales of facilities		—			—			—			(5	)		—			(5	)
Legal claim costs		—			22			—			—			—			22
Amortization of debt issuance costs		—			18			—			—			—			18
Share-based compensation		—			—			129			—			—			129
Equity in earnings of affiliates		(1,270	)		—			—			—			1,270			—
Other		37			—			(2	)		2			—			37
Net cash provided by (used in) operating activities		163			(741	)		2,027			1,299			—			2,748
Cash flows from investing activities:
Purchase of property and equipment		—			—			(482	)		(690	)		—			(1,172	)
Acquisition of hospitals and health care entities		—			—			(148	)		(282	)		—			(430	)
Disposition of hospitals and health care entities		—			—			9			5			—			14
Change in investments		—			—			3			15			—			18
Other		—			—			(1	)		16			—			15
Net cash used in investing activities		—			—			(619	)		(936	)		—			(1,555	)
Cash flows from financing activities:
Issuance of long-term debt		—			3,000			—			—			—			3,000
Repayment of long-term debt		—			(2,005	)		(38	)		(22	)		—			(2,065	)
Distributions to noncontrolling interests		—			—			(29	)		(176	)		—			(205	)
Payment of debt issuance costs		—			(24	)		—			—			—			(24	)
Repurchases of common stock		(1,858	)		—			—			—			—			(1,858	)
Changes in intercompany balances with affiliates, net		1,799			(230	)		(1,414	)		(155	)		—			—
Other		(104	)		—			—			13			—			(91	)
Net cash (used in) provided by financing activities		(163	)		741			(1,481	)		(340	)		—			(1,243	)
Change in cash and cash equivalents		—			—			(73	)		23			—			(50	)
Cash and cash equivalents at beginning of period		—			—			155			586			—			741
Cash and cash equivalents at end of period	$	—		$	—		$	82		$	609		$	—		$	691

XML

Basis of Presentation and Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature.

The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $92 million and $93 million for the quarters ended June 30, 2017 and 2016, respectively, and $182 million and $178 million for the six months ended June 30, 2017 and 2016, respectively. Operating results for the quarter and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2016.

Revenues

Revenues

Revenues are recorded during the period the health care services are provided, based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans and commercial insurance companies (including plans offered through the health insurance exchanges), and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record a provision for doubtful accounts (based primarily on historical collection experience) related to uninsured accounts to record net self-pay revenues at the estimated amounts we expect to collect. Our revenues from third-party payers, the uninsured and other for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter
	2017			Ratio			2016			Ratio
Medicare	$	2,321			21.6	%	$	2,217			21.5	%
Managed Medicare		1,187			11.1			1,078			10.4
Medicaid		453			4.2			416			4.0
Managed Medicaid		575			5.4			608			5.9
Managed care and other insurers		6,106			56.9			5,759			55.8
International (managed care and other insurers)		269			2.5			324			3.1
		10,911			101.7			10,402			100.7
Uninsured		519			4.8			225			2.2
Other		376			3.5			454			4.4
Revenues before provision for doubtful accounts		11,806			110.0			11,081			107.3
Provision for doubtful accounts		(1,073	)		(10.0	)		(762	)		(7.3	)
Revenues	$	10,733			100.0	%	$	10,319			100.0	%

	Six Months
	2017			Ratio			2016			Ratio
Medicare	$	4,726			22.1	%	$	4,483			21.8	%
Managed Medicare		2,390			11.2			2,182			10.6
Medicaid		826			3.9			843			4.1
Managed Medicaid		1,216			5.7			1,205			5.9
Managed care and other insurers		12,032			56.3			11,461			55.7
International (managed care and other insurers)		538			2.5			641			3.1
		21,728			101.7			20,815			101.2
Uninsured		744			3.5			414			2.0
Other		717			3.4			902			4.4
Revenues before provision for doubtful accounts		23,189			108.6			22,131			107.6
Provision for doubtful accounts		(1,833	)		(8.6	)		(1,552	)		(7.6	)
Revenues	$	21,356			100.0	%	$	20,579			100.0	%

Recent Pronouncements

Recent Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) and the International Accounting Standards Board issued a final, converged, principles-based standard on revenue recognition. Companies across all industries will use a five-step model to recognize revenue from customer contracts. The new standard, which replaces nearly all existing revenue recognition guidance, will require significant management judgments and change the way many companies recognize revenue in their financial statements. In July 2015, the FASB decided to defer the effective date of the new revenue standard by one year to annual and interim periods beginning after December 15, 2017 for public entities and permit entities to adopt one year earlier if they choose. The FASB decided, based on its outreach to various stakeholders and continuing amendments to the new revenue standard, that a deferral was necessary to provide adequate time to effectively implement the new standard. We are continuing to evaluate the effects the adoption of this standard will have on our financial statements and financial disclosures. We believe the most significant impact will be to the presentation of our income statement where the provision for doubtful accounts will be recorded as a direct reduction to revenues and will not be presented as a separate line item. We expect to adopt the new standard using the full retrospective application, and we do not currently believe the adoption will have a significant impact on our recognition of net revenues or related disclosures for any period.

In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for most leases. ASU 2016-02 is effective for public business entities for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. ASU 2016-02’s transition provisions will be applied using a modified retrospective approach at the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the provisions of ASU 2016-02 to determine how our financial statements will be affected, and we believe the primary effect of adopting the new standard will be to record right-of-use assets and obligations for our leases currently classified as operating leases.

Reclassifications

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Earning Per Share

We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards and potential shares, computed using the treasury stock method.

Fair Value Measurements and Disclosures

Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC 820”) emphasizes fair value is a market-based measurement, and fair value measurements should be determined based on the assumptions market participants would use in pricing assets or liabilities. ASC 820 utilizes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment.

Cash Traded Investments

Cash Traded Investments

Our cash traded investments are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Certain types of cash traded instruments are classified within Level 3 of the fair value hierarchy because they trade infrequently and therefore have little or no price transparency. The valuation of these securities involves the consideration of market factors and management’s judgment.

Derivative Financial Instruments

Derivative Financial Instruments

We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments.

Although we determined the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with our derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. We assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative positions, and at June 30, 2017 and December 31, 2016, we determined the credit valuation adjustments were not significant to the overall valuation of our derivatives.

Interest Rate Swaps [Member]

Interest Rate Swap Agreements

Interest Rate Swap Agreements

We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between two parties based on common notional principal amounts and maturity dates. Pay-fixed interest rate swaps effectively convert LIBOR indexed variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions.

XML

Basis of Presentation and Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Schedule of Revenues from Third Party Payers, Uninsured and Other Payers

Our revenues from third party payers, the uninsured and other for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter
	2017			Ratio			2016			Ratio
Medicare	$	2,321			21.6	%	$	2,217			21.5	%
Managed Medicare		1,187			11.1			1,078			10.4
Medicaid		453			4.2			416			4.0
Managed Medicaid		575			5.4			608			5.9
Managed care and other insurers		6,106			56.9			5,759			55.8
International (managed care and other insurers)		269			2.5			324			3.1
		10,911			101.7			10,402			100.7
Uninsured		519			4.8			225			2.2
Other		376			3.5			454			4.4
Revenues before provision for doubtful accounts		11,806			110.0			11,081			107.3
Provision for doubtful accounts		(1,073	)		(10.0	)		(762	)		(7.3	)
Revenues	$	10,733			100.0	%	$	10,319			100.0	%

	Six Months
	2017			Ratio			2016			Ratio
Medicare	$	4,726			22.1	%	$	4,483			21.8	%
Managed Medicare		2,390			11.2			2,182			10.6
Medicaid		826			3.9			843			4.1
Managed Medicaid		1,216			5.7			1,205			5.9
Managed care and other insurers		12,032			56.3			11,461			55.7
International (managed care and other insurers)		538			2.5			641			3.1
		21,728			101.7			20,815			101.2
Uninsured		744			3.5			414			2.0
Other		717			3.4			902			4.4
Revenues before provision for doubtful accounts		23,189			108.6			22,131			107.6
Provision for doubtful accounts		(1,833	)		(8.6	)		(1,552	)		(7.6	)
Revenues	$	21,356			100.0	%	$	20,579			100.0	%

XML

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Computations of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the quarters and six months ended June 30, 2017 and 2016 (dollars and shares in millions, except per share amounts):

	Quarter				Six Months
	2017		2016		2017		2016
Net income attributable to HCA Healthcare, Inc.	$	657	$	658	$	1,316	$	1,352
Weighted average common shares outstanding		365.847		386.406		368.056		391.401
Effect of dilutive incremental shares		9.491		12.253		9.591		13.216
Shares used for diluted earnings per share		375.338		398.659		377.647		404.617
Earnings per share:
Basic earnings per share	$	1.79	$	1.70	$	3.58	$	3.45
Diluted earnings per share	$	1.75	$	1.65	$	3.48	$	3.34

XML

Investments of Insurance Subsidiaries (Tables)

6 Months Ended

Jun. 30, 2017

Investments, Debt and Equity Securities [Abstract]

Schedule of Investments

A summary of our insurance subsidiaries’ investments at June 30, 2017 and December 31, 2016 follows (dollars in millions):

	June 30, 2017
	Amortized Cost		Unrealized Amounts				Fair Value
			Gains		Losses
Debt securities:
States and municipalities	$	364		$14		$—	$	378
Money market funds		20		—		—		20
		384		14		—		398
Equity securities		1		2		—		3
	$	385		$16		$—		401
Amounts classified as current assets								(49	)
Investment carrying value							$	352

	December 31, 2016
	Amortized Cost		Unrealized Amounts				Fair Value
			Gains		Losses
Debt securities:
States and municipalities	$	345		$9		$(1)	$	353
Money market funds		28		—		—		28
		373		9		(1)		381
Equity securities		1		3		—		4
	$	374		$12		$(1)		385
Amounts classified as current assets								(49	)
Investment carrying value							$	336

Schedule of Maturities of Investments

Scheduled maturities of investments in debt securities at June 30, 2017 were as follows (dollars in millions):

	Amortized Cost		Fair Value
Due in one year or less	$	96	$	96
Due after one year through five years		71		74
Due after five years through ten years		174		184
Due after ten years		43		44
	$	384	$	398

XML

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges

The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at June 30, 2017 (dollars in millions):

	Notional Amount		Maturity Date		Fair Value
Pay-fixed interest rate swaps	$	1,000		December 2017	$	(5	)
Pay-fixed interest rate swaps		2,000		December 2021		29

Effect of Interest Rate on Results of Operations

The following table presents the effect of our interest rate swaps on our results of operations for the six months ended June 30, 2017 (dollars in millions):

Derivatives in Cash Flow Hedging Relationships	Amount of Loss Recognized in OCI on Derivatives, Net of  Tax		Location of Loss Reclassified from Accumulated OCI into Operations		Amount of Loss Reclassified from Accumulated OCI into Operations
Interest rate swaps	$	5		Interest expense	$	13

XML

Assets and Liabilities Measured at Fair Value (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions):

	June 30, 2017
				Fair Value Measurements Using
	Fair Value			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Assets:
Investments of insurance subsidiaries:
Debt securities:
States and municipalities	$	378		$	—		$	378		$	—
Money market funds		20			20			—			—
		398			20			378			—
Equity securities		3			3			—			—
Investments of insurance subsidiaries		401			23			378			—
Less amounts classified as current assets		(49	)		(20	)		(29	)		—
	$	352		$	3		$	349		$	—
Interest rate swaps (Other)	$	29		$	—		$	29		$	—
Liabilities:
Interest rate swaps (Income taxes and other liabilities)	$	5		$	—		$	5		$	—
	December 31, 2016
				Fair Value Measurements Using
	Fair Value			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Assets:
Investments of insurance subsidiaries:
Debt securities:
States and municipalities	$	353		$	—		$	347		$	6
Money market funds		28			28			—			—
		381			28			347			6
Equity securities		4			4			—			—
Investments of insurance subsidiaries		385			32			347			6
Less amounts classified as current assets		(49	)		(28	)		(21	)		—
	$	336		$	4		$	326		$	6
Interest rate swaps (Other)	$	31		$	—		$	31		$	—
Liabilities:
Interest rate swaps (Income taxes and other liabilities)	$	12		$	—		$	12		$	—

XML

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

A summary of long-term debt at June 30, 2017 and December 31, 2016, including related interest rates at June 30, 2017, follows (dollars in millions):

	June 30, 2017			December 31, 2016
Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)	$	1,760		$	2,920
Senior secured revolving credit facility		—			—
Senior secured term loan facilities (effective interest rate of 3.6%)		3,939			3,981
Senior secured notes (effective interest rate of 5.4%)		15,300			13,800
Other senior secured debt (effective interest rate of 5.8%)		589			593
Senior secured debt		21,588			21,294
Senior unsecured notes (effective interest rate of 6.5%)		10,252			10,252
Net debt issuance costs		(179	)		(170	)
Total debt (average life of 7.3 years, rates averaging 5.4%)		31,661			31,376
Less amounts due within one year		213			216
	$	31,448		$	31,160

XML

Capital Structure (Tables)

6 Months Ended

Jun. 30, 2017

Text Block [Abstract]

Schedule of Changes in Stockholders' Deficit and Equity

The changes in stockholders’ deficit, including changes in stockholders’ deficit attributable to HCA Healthcare, Inc. and changes in equity attributable to noncontrolling interests, are as follows (dollars and shares in millions):

	Equity (Deficit) Attributable to HCA Healthcare, Inc.														Equity Attributable to Noncontrolling Interests			Total
	Common Stock					Capital in Excess of Par Value			Accumulated Other Comprehensive Loss			Retained Deficit
	Shares			Par Value
Balances at December 31, 2016		370.536		$	4	$	—		$	(338	)	$	(6,968	)	$	1,669		$	(5,633	)
Comprehensive income		—			—		—			45			1,316			256			1,617
Repurchase of common stock		(11.525	)		—		(115	)		—			(851	)		—			(966	)
Distributions		—			—		—			—			—			(248	)		(248	)
Share-based benefit plans		3.884			—		117			—			—			—			117
Other		—			—		(2	)		—			—			36			34
Balances at June 30, 2017		362.895		$	4	$	—		$	(293	)	$	(6,503	)	$	1,713		$	(5,079	)

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (dollars in millions):

	Unrealized Gains on Available- for-Sale Securities		Foreign Currency Translation Adjustments			Defined Benefit Plans			Change in Fair Value of Derivative Instruments			Total
Balances at December 31, 2016	$	7	$	(211	)	$	(146	)	$	12		$	(338	)
Unrealized gains on available-for-sale securities, net of $2 of income taxes		3		—			—			—			3
Foreign currency translation adjustments, net of $22 of income taxes		—		33			—			—			33
Change in fair value of derivative instruments, net of $3 income tax benefits		—		—			—			(5	)		(5	)
Expense reclassified into operations from other comprehensive income, net of $3 and $5, respectively, income tax benefits		—		—			6			8			14
Balances at June 30, 2017	$	10	$	(178	)	$	(140	)	$	15		$	(293	)

XML

Segment and Geographic Information (Tables)

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA and Depreciation and Amortization

The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters and six months ended June 30, 2017 and 2016 are summarized in the following table (dollars in millions):

	Quarter						Six Months
	2017			2016			2017			2016
Revenues:
National Group	$	5,160		$	4,931		$	10,308		$	9,898
American Group		5,093			4,860			10,088			9,646
Corporate and other		480			528			960			1,035
	$	10,733		$	10,319		$	21,356		$	20,579
Equity in earnings of affiliates:
National Group	$	(4	)	$	(2	)	$	(9	)	$	(4	)
American Group		(10	)		(8	)		(18	)		(17	)
Corporate and other		1			—			4			(1	)
	$	(13	)	$	(10	)	$	(23	)	$	(22	)
Adjusted segment EBITDA:
National Group	$	1,162		$	1,131		$	2,293		$	2,269
American Group		1,040			1,004			2,047			1,986
Corporate and other		(112	)		(83	)		(245	)		(200	)
	$	2,090		$	2,052		$	4,095		$	4,055
Depreciation and amortization:
National Group	$	217		$	201		$	431		$	398
American Group		238			225			476			444
Corporate and other		66			63			135			126
	$	521		$	489		$	1,042		$	968
Adjusted segment EBITDA	$	2,090		$	2,052		$	4,095		$	4,055
Depreciation and amortization		521			489			1,042			968
Interest expense		411			427			830			843
Gains on sales of facilities		(2	)		(6	)		(3	)		(5	)
Legal claim costs		—			10			—			22
Income before income taxes	$	1,160		$	1,132		$	2,226		$	2,227

XML

Supplemental Condensed Consolidating Financial Information (Tables)

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Condensed Consolidating Comprehensive Income Statement

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE QUARTER ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	6,049		$	5,757		$	—		$	11,806
Provision for doubtful accounts		—			—			593			480			—			1,073
Revenues		—			—			5,456			5,277			—			10,733
Salaries and benefits		—			—			2,437			2,459			—			4,896
Supplies		—			—			931			864			—			1,795
Other operating expenses		4			—			951			1,010			—			1,965
Equity in earnings of affiliates		(658	)		—			(1	)		(12	)		658			(13	)
Depreciation and amortization		—			—			248			273			—			521
Interest expense		16			755			(291	)		(69	)		—			411
Gains on sales of facilities		—			—			(1	)		(1	)		—			(2	)
Management fees		—			—			(212	)		212			—			—
		(638	)		755			4,062			4,736			658			9,573
Income (loss) before income taxes		638			(755	)		1,394			541			(658	)		1,160
Provision (benefit) for income taxes		(19	)		(279	)		505			158			—			365
Net income (loss)		657			(476	)		889			383			(658	)		795
Net income attributable to noncontrolling interests		—			—			27			111			—			138
Net income (loss) attributable to HCA Healthcare, Inc.	$	657		$	(476	)	$	862		$	272		$	(658	)	$	657
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	684		$	(480	)	$	865		$	300		$	(685	)	$	684

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE QUARTER ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	5,693		$	5,388		$	—		$	11,081
Provision for doubtful accounts		—			—			498			264			—			762
Revenues		—			—			5,195			5,124			—			10,319
Salaries and benefits		—			—			2,347			2,344			—			4,691
Supplies		—			—			886			832			—			1,718
Other operating expenses		2			—			893			973			—			1,868
Equity in earnings of affiliates		(641	)		—			(1	)		(9	)		641			(10	)
Depreciation and amortization		—			—			238			251			—			489
Interest expense		16			670			(204	)		(55	)		—			427
Gains on sales of facilities		—			—			(2	)		(4	)		—			(6	)
Legal claim costs		—			10			—			—			—			10
Management fees		—			—			(235	)		235			—			—
		(623	)		680			3,922			4,567			641			9,187
Income (loss) before income taxes		623			(680	)		1,273			557			(641	)		1,132
Provision (benefit) for income taxes		(35	)		(251	)		462			165			—			341
Net income (loss)		658			(429	)		811			392			(641	)		791
Net income attributable to noncontrolling interests		—			—			21			112			—			133
Net income (loss) attributable to HCA Healthcare, Inc.	$	658		$	(429	)	$	790		$	280		$	(641	)	$	658
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	608		$	(431	)	$	794		$	228		$	(591	)	$	608

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	11,902		$	11,287		$	—		$	23,189
Provision for doubtful accounts		—			—			1,012			821			—			1,833
Revenues		—			—			10,890			10,466			—			21,356
Salaries and benefits		—			—			4,903			4,894			—			9,797
Supplies		—			—			1,882			1,710			—			3,592
Other operating expenses		5			—			1,878			2,012			—			3,895
Equity in earnings of affiliates		(1,266	)		—			(2	)		(21	)		1,266			(23	)
Depreciation and amortization		—			—			499			543			—			1,042
Interest expense		32			1,488			(560	)		(130	)		—			830
Gains on sales of facilities		—			—			(1	)		(2	)		—			(3	)
Management fees		—			—			(422	)		422			—			—
		(1,229	)		1,488			8,177			9,428			1,266			19,130
Income (loss) before income taxes		1,229			(1,488	)		2,713			1,038			(1,266	)		2,226
Provision (benefit) for income taxes		(87	)		(549	)		983			307			—			654
Net income (loss)		1,316			(939	)		1,730			731			(1,266	)		1,572
Net income attributable to noncontrolling interests		—			—			50			206			—			256
Net income (loss) attributable to HCA Healthcare, Inc.	$	1,316		$	(939	)	$	1,680		$	525		$	(1,266	)	$	1,316
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	1,361		$	(936	)	$	1,686		$	561		$	(1,311	)	$	1,361

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING COMPREHENSIVE INCOME STATEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Revenues before provision for doubtful accounts	$	—		$	—		$	11,366		$	10,765		$	—		$	22,131
Provision for doubtful accounts		—			—			992			560			—			1,552
Revenues		—			—			10,374			10,205			—			20,579
Salaries and benefits		—			—			4,701			4,692			—			9,393
Supplies		—			—			1,784			1,648			—			3,432
Other operating expenses		4			—			1,750			1,967			—			3,721
Equity in earnings of affiliates		(1,270	)		—			(3	)		(19	)		1,270			(22	)
Depreciation and amortization		—			—			465			503			—			968
Interest expense		32			1,320			(411	)		(98	)		—			843
Gains on sales of facilities		—			—			—			(5	)		—			(5	)
Legal claim costs		—			22			—			—			—			22
Management fees		—			—			(395	)		395			—			—
		(1,234	)		1,342			7,891			9,083			1,270			18,352
Income (loss) before income taxes		1,234			(1,342	)		2,483			1,122			(1,270	)		2,227
Provision (benefit) for income taxes		(118	)		(495	)		900			338			—			625
Net income (loss)		1,352			(847	)		1,583			784			(1,270	)		1,602
Net income attributable to noncontrolling interests		—			—			43			207			—			250
Net income (loss) attributable to HCA Healthcare, Inc.	$	1,352		$	(847	)	$	1,540		$	577		$	(1,270	)	$	1,352
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$	1,273		$	(856	)	$	1,546		$	501		$	(1,191	)	$	1,273

Schedule of Condensed Consolidating Balance Sheet

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING BALANCE SHEET

JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors		Eliminations			Condensed Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—		$	—		$	155		$	550	$	—		$	705
Accounts receivable, net		—			—			2,991			2,791		—			5,782
Inventories		—			—			923			621		—			1,544
Other		—			—			522			784		—			1,306
		—			—			4,591			4,746		—			9,337
Property and equipment, net		—			—			8,560			8,208		—			16,768
Investments of insurance subsidiaries		—			—			—			352		—			352
Investments in and advances to affiliates		28,356			—			15			182		(28,356	)		197
Goodwill and other intangible assets		—			—			1,727			5,044		—			6,771
Other		805			29			33			274		—			1,141
	$	29,161		$	29		$	14,926		$	18,806	$	(28,356	)	$	34,566
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	—		$	—		$	1,342		$	903	$	—		$	2,245
Accrued salaries		—			—			679			530		—			1,209
Other accrued expenses		281			383			457			983		—			2,104
Long-term debt due within one year		—			97			57			59		—			213
		281			480			2,535			2,475		—			5,771
Long-term debt, net		994			29,981			188			285		—			31,448
Intercompany balances		34,258			(9,404	)		(27,765	)		2,911		—			—
Professional liability risks		—			—			—			1,144		—			1,144
Income taxes and other liabilities		420			5			403			454		—			1,282
		35,953			21,062			(24,639)			7,269		—			39,645
Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc.		(6,792	)		(21,033	)		39,438			9,951		(28,356	)		(6,792	)
Noncontrolling interests		—			—			127			1,586		—			1,713
		(6,792	)		(21,033	)		39,565			11,537		(28,356	)		(5,079	)
	$	29,161		$	29		$	14,926		$	18,806	$	(28,356	)	$	34,566

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING BALANCE SHEET

DECEMBER 31, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors		Eliminations			Condensed Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—		$	—		$	110		$	536	$	—		$	646
Accounts receivable, net		—			—			3,028			2,798		—			5,826
Inventories		—			—			890			613		—			1,503
Other		—			—			445			666		—			1,111
		—			—			4,473			4,613		—			9,086
Property and equipment, net		—			—			8,463			7,889		—			16,352
Investments of insurance subsidiaries		—			—			—			336		—			336
Investments in and advances to affiliates		27,045			—			16			190		(27,045	)		206
Goodwill and other intangible assets		—			—			1,728			4,976		—			6,704
Other		877			—			34			163		—			1,074
	$	27,922		$	—		$	14,714		$	18,167	$	(27,045	)	$	33,758
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$	—		$	—		$	1,439		$	879	$	—		$	2,318
Accrued salaries		—			—			704			561		—			1,265
Other accrued expenses		29			572			464			970		—			2,035
Long-term debt due within one year		—			97			60			59		—			216
		29			669			2,667			2,469		—			5,834
Long-term debt, net		993			29,693			199			275		—			31,160
Intercompany balances		33,784			(10,277	)		(26,447	)		2,940		—			—
Professional liability risks		—			—			—			1,148		—			1,148
Income taxes and other liabilities		418			12			387			432		—			1,249
		35,224			20,097			(23,194	)		7,264		—			39,391
Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc.		(7,302	)		(20,097	)		37,752			9,390		(27,045	)		(7,302	)
Noncontrolling interests		—			—			156			1,513		—			1,669
		(7,302	)		(20,097	)		37,908			10,903		(27,045	)		(5,633	)
	$	27,922		$	—		$	14,714		$	18,167	$	(27,045	)	$	33,758

Schedule of Condensed Consolidating Statement of Cash Flows

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2017

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Cash flows from operating activities:
Net income (loss)	$	1,316		$	(939	)	$	1,730		$	731		$	(1,266	)	$	1,572
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities		1			(189	)		(1,189	)		(851	)		—			(2,228	)
Provision for doubtful accounts		—			—			1,012			821			—			1,833
Depreciation and amortization		—			—			499			543			—			1,042
Income taxes		267			—			—			—			—			267
Gains on sales of facilities		—			—			(1	)		(2	)		—			(3	)
Amortization of debt issuance costs		—			16			—			—			—			16
Share-based compensation		—			—			140			—			—			140
Equity in earnings of affiliates		(1,266	)		—			—			—			1,266			—
Other		39			—			—			6			—			45
Net cash provided by (used in) operating activities		357			(1,112	)		2,191			1,248			—			2,684
Cash flows from investing activities:
Purchase of property and equipment		—			—			(578	)		(726	)		—			(1,304	)
Acquisition of hospitals and health care entities		—			—			(5	)		(290	)		—			(295	)
Disposition of hospitals and health care entities		—			—			10			4			—			14
Change in investments		—			—			—			(11	)		—			(11	)
Other		—			—			2			3			—			5
Net cash used in investing activities		—			—			(571	)		(1,020	)		—			(1,591	)
Cash flows from financing activities:
Issuance of long-term debt		—			1,500			—			2			—			1,502
Net change in revolving credit facilities		—			(1,160	)		—			—			—			(1,160	)
Repayment of long-term debt		—			(42	)		(33	)		(20	)		—			(95	)
Distributions to noncontrolling interests		—			—			(79	)		(169	)		—			(248	)
Payment of debt issuance costs		—			(25	)		—			—			—			(25	)
Repurchases of common stock		(966	)		—			—			—			—			(966	)
Changes in intercompany balances with affiliates, net		671			839			(1,463	)		(47	)		—			—
Other		(62	)		—			—			20			—			(42	)
Net cash (used in) provided by financing activities		(357	)		1,112			(1,575	)		(214	)		—			(1,034	)
Change in cash and cash equivalents		—			—			45			14			—			59
Cash and cash equivalents at beginning of period		—			—			110			536			—			646
Cash and cash equivalents at end of period	$	—		$	—		$	155		$	550		$	—		$	705

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2016

(Dollars in millions)

	HCA Healthcare, Inc. Issuer			HCA Inc. Issuer			Subsidiary Guarantors			Subsidiary Non- Guarantors			Eliminations			Condensed Consolidated
Cash flows from operating activities:
Net income (loss)	$	1,352		$	(847	)	$	1,583		$	784		$	(1,270	)	$	1,602
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities		(23	)		66			(1,140	)		(545	)		—			(1,642	)
Provision for doubtful accounts		—			—			992			560			—			1,552
Depreciation and amortization		—			—			465			503			—			968
Income taxes		67			—			—			—			—			67
Gains on sales of facilities		—			—			—			(5	)		—			(5	)
Legal claim costs		—			22			—			—			—			22
Amortization of debt issuance costs		—			18			—			—			—			18
Share-based compensation		—			—			129			—			—			129
Equity in earnings of affiliates		(1,270	)		—			—			—			1,270			—
Other		37			—			(2	)		2			—			37
Net cash provided by (used in) operating activities		163			(741	)		2,027			1,299			—			2,748
Cash flows from investing activities:
Purchase of property and equipment		—			—			(482	)		(690	)		—			(1,172	)
Acquisition of hospitals and health care entities		—			—			(148	)		(282	)		—			(430	)
Disposition of hospitals and health care entities		—			—			9			5			—			14
Change in investments		—			—			3			15			—			18
Other		—			—			(1	)		16			—			15
Net cash used in investing activities		—			—			(619	)		(936	)		—			(1,555	)
Cash flows from financing activities:
Issuance of long-term debt		—			3,000			—			—			—			3,000
Repayment of long-term debt		—			(2,005	)		(38	)		(22	)		—			(2,065	)
Distributions to noncontrolling interests		—			—			(29	)		(176	)		—			(205	)
Payment of debt issuance costs		—			(24	)		—			—			—			(24	)
Repurchases of common stock		(1,858	)		—			—			—			—			(1,858	)
Changes in intercompany balances with affiliates, net		1,799			(230	)		(1,414	)		(155	)		—			—
Other		(104	)		—			—			13			—			(91	)
Net cash (used in) provided by financing activities		(163	)		741			(1,481	)		(340	)		—			(1,243	)
Change in cash and cash equivalents		—			—			(73	)		23			—			(50	)
Cash and cash equivalents at beginning of period		—			—			155			586			—			741
Cash and cash equivalents at end of period	$	—		$	—		$	82		$	609		$	—		$	691

XML

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($) State Hospital Surgery_Center	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) State Hospital Surgery_Center	Jun. 30, 2016 USD ($)
Accounting Policies [Abstract]
Entity information, former legal or registered name			HCA Holdings, Inc.
Number of owned and operated hospitals | Hospital	172		172
Number of freestanding surgery centers | Surgery_Center	119		119
Number of facilities locations | State	20		20
General and administrative expense | $	$ 92	$ 93	$ 182	$ 178

XML

Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 10,911	$ 10,402	$ 21,728	$ 20,815
Uninsured	519	225	744	414
Other	376	454	717	902
Revenues before provision for doubtful accounts	11,806	11,081	23,189	22,131
Provision for doubtful accounts	(1,073)	(762)	(1,833)	(1,552)
Revenues	$ 10,733	$ 10,319	$ 21,356	$ 20,579
Revenues from third party payers, Ratio	101.70%	100.70%	101.70%	101.20%
Uninsured, Ratio	4.80%	2.20%	3.50%	2.00%
Other, Ratio	3.50%	4.40%	3.40%	4.40%
Revenues before provision for doubtful accounts, Ratio	110.00%	107.30%	108.60%	107.60%
Provision for doubtful accounts, Ratio	(10.00%)	(7.30%)	(8.60%)	(7.60%)
Revenues ratio from third party payers	100.00%	100.00%	100.00%	100.00%
Medicare [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 2,321	$ 2,217	$ 4,726	$ 4,483
Revenues from third party payers, Ratio	21.60%	21.50%	22.10%	21.80%
Managed Medicare [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 1,187	$ 1,078	$ 2,390	$ 2,182
Revenues from third party payers, Ratio	11.10%	10.40%	11.20%	10.60%
Medicaid [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 453	$ 416	$ 826	$ 843
Revenues from third party payers, Ratio	4.20%	4.00%	3.90%	4.10%
Managed Medicaid [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 575	$ 608	$ 1,216	$ 1,205
Revenues from third party payers, Ratio	5.40%	5.90%	5.70%	5.90%
Managed Care and Other Insurers [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 6,106	$ 5,759	$ 12,032	$ 11,461
Revenues from third party payers, Ratio	56.90%	55.80%	56.30%	55.70%
International (Managed Care and Other Insurers) [Member]
Revenues From Third Party Payers [Line Items]
Revenues from third party payers	$ 269	$ 324	$ 538	$ 641
Revenues from third party payers, Ratio	2.50%	3.10%	2.50%	3.10%

XML

Acquisitions and Dispositions - Additional Information (Detail) $ in Millions		6 Months Ended
	Jul. 01, 2017	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Business Acquisition [Line Items]
Number of hospitals purchased		3	3
Proceeds from sale of business		$ 14	$ 14
Real Estate and Other Investments [Member]
Business Acquisition [Line Items]
Proceeds from sale of business		14	14
Pretax gain (loss) on sales of business		3	5
Hospitals [Member]
Business Acquisition [Line Items]
Aggregate purchase price		189	343
Nonhospital Health Care [Member]
Business Acquisition [Line Items]
Aggregate purchase price		$ 106	$ 87
Subsequent Event [Member]
Business Acquisition [Line Items]
Number of hospitals purchased	2

XML

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Liability for unrecognized tax benefits	$ 420		$ 420		$ 418
Unrecognized tax benefits, accrued interest	46		46		45
Unrecognized tax benefits that would impact effective tax rate	141		141		$ 137
Provision for tax benefits related to settlement of employee awards	9	$ 44	76	$ 118
Reductions in interest (net of tax) related to taxing authority examinations	$ 10		$ 12

XML

Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Net income attributable to HCA Healthcare, Inc.	$ 657	$ 658	$ 1,316	$ 1,352
Weighted average common shares outstanding	365,847	386,406	368,056	391,401
Effect of dilutive incremental shares	9,491	12,253	9,591	13,216
Shares used for diluted earnings per share	375,338	398,659	377,647	404,617
Basic earnings per share	$ 1.79	$ 1.70	$ 3.58	$ 3.45
Diluted earnings per share	$ 1.75	$ 1.65	$ 3.48	$ 3.34

XML

Investments of Insurance Subsidiaries - Schedule of Investments (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 385	$ 374
Unrealized Amounts, Gains	16	12
Unrealized Amounts, Losses		(1)
Fair Value	401	385
Amounts classified as current assets	(49)	(49)
Investment carrying value	352	336
Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	384	373
Unrealized Amounts, Gains	14	9
Unrealized Amounts, Losses		(1)
Fair Value	398	381
Debt Securities [Member] | States and Municipalities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	364	345
Unrealized Amounts, Gains	14	9
Unrealized Amounts, Losses		(1)
Fair Value	378	353
Debt Securities [Member] | Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20	28
Fair Value	20	28
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1	1
Unrealized Amounts, Gains	2	3
Fair Value	$ 3	$ 4

XML

Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail) $ in Millions	Jun. 30, 2017 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in one year or less, Amortized Cost	$ 96
Due after one year through five years, Amortized Cost	71
Due after five years through ten years, Amortized Cost	174
Due after ten years, Amortized Cost	43
Amortized Cost, Total	384
Due in one year or less, Fair Value	96
Due after one year through five years, Fair Value	74
Due after five years through ten years, Fair Value	184
Due after ten years, Fair Value	44
Fair Value, Total	$ 398

XML

Investments of Insurance Subsidiaries - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Available for sale securities expected maturity of debt securities	3 years 10 months 24 days
Available for sale securities average scheduled maturity	5 years 6 months

XML

Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail) - Pay-Fixed Interest Rate Swaps [Member]	6 Months Ended
	Jun. 30, 2017 USD ($)
Maturity Date, 2017 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 1,000,000,000
Fair Value	$ (5,000,000)
Maturity Date	Dec. 31, 2017
Maturity Date, 2021 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 2,000,000,000
Fair Value	$ 29,000,000
Maturity Date	Dec. 31, 2021

XML

Financial Instruments - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2017 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Estimated amount reclassified from other comprehensive income to interest expense	$ 8

XML

Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense	$ 411	$ 427	$ 830	$ 843
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Recognized in OCI on Derivatives, Net of Tax			5
Reclassification out of Accumulated Other Comprehensive Income [Member] | Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense			$ 13

XML

Assets and Liabilities Measured at Fair Value - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	$ 401	$ 385
Less amounts classified as current assets	(49)	(49)
Investments of insurance subsidiaries, noncurrent	352	336
Interest Rate Swaps [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Interest rate swaps (Other)	29	31
Liabilities, Fair Value	5	12
Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	398	381
Debt Securities [Member] | States and Municipalities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	378	353
Debt Securities [Member] | Money Market Funds [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	20	28
Equity Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	3	4
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	23	32
Less amounts classified as current assets	(20)	(28)
Investments of insurance subsidiaries, noncurrent	3	4
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member] | Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	20	28
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member] | Debt Securities [Member] | Money Market Funds [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	20	28
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member] | Equity Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	3	4
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	378	347
Less amounts classified as current assets	(29)	(21)
Investments of insurance subsidiaries, noncurrent	349	326
Significant Other Observable Inputs (Level 2) [Member] | Interest Rate Swaps [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Interest rate swaps (Other)	29	31
Liabilities, Fair Value	5	12
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	378	347
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | States and Municipalities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value	$ 378	347
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value		6
Investments of insurance subsidiaries, noncurrent		6
Significant Unobservable Inputs (Level 3) [Member] | Debt Securities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value		6
Significant Unobservable Inputs (Level 3) [Member] | Debt Securities [Member] | States and Municipalities [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Fair Value		$ 6

XML

Assets and Liabilities Measured at Fair Value - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated fair value of long-term debt	$ 33,802	$ 32,833
Carrying amounts of long-term debt	31,840	$ 31,546
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Reduction of insurance subsidiaries resulted from settlements	$ 6

XML

Long-Term Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Senior secured debt	$ 21,588	$ 21,294
Net debt issuance costs	(179)	(170)
Total debt (average life of 7.3 years, rates averaging 5.4%)	31,661	31,376
Less amounts due within one year	213	216
Long-term debt	31,448	31,160
Senior Secured Asset-Based Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term line of credit	1,760	2,920
Senior Secured Term Loan Facilities [Member]
Debt Instrument [Line Items]
Senior secured debt	3,939	3,981
Senior Secured Notes [Member]
Debt Instrument [Line Items]
Senior secured debt	15,300	13,800
Other Senior Secured Debt [Member]
Debt Instrument [Line Items]
Other senior secured debt	589	593
Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Senior unsecured notes	$ 10,252	$ 10,252

XML

Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2017
Debt Instrument [Line Items]
Total debt average term	7 years 3 months 19 days
Total debt average rate	5.40%
Senior Secured Asset-Based Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Effective interest rate	2.70%
Senior Secured Term Loan Facilities [Member]
Debt Instrument [Line Items]
Effective interest rate	3.60%
Senior Secured Notes [Member]
Debt Instrument [Line Items]
Effective interest rate	5.40%
Other Senior Secured Debt [Member]
Debt Instrument [Line Items]
Effective interest rate	5.80%
Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Effective interest rate	6.50%

XML

Long-Term Debt - Additional Information (Detail) - USD ($)	1 Months Ended
	Jun. 30, 2017	Aug. 31, 2016	Mar. 31, 2016
Asset-Based Revolving Credit Facility Maturing on June 28, 2022 [Member]
Debt Instrument [Line Items]
Credit facility, maximum amount	$ 3,750,000,000
Debt instrument maturity date	Jun. 28, 2022
Additional incremental credit facilities	$ 1,500,000,000
Credit facility, commitment fee for unutilized commitments	0.25%
Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument maturity date	Oct. 31, 2018	Feb. 29, 2024	Mar. 31, 2023
Senior Notes [Member] | Senior Secured Notes Due 2026 [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount			$ 1,500,000,000
Debt instrument, stated interest			5.25%
Senior Notes [Member] | Senior Secured Notes Due 2023 [Member]
Debt Instrument [Line Items]
Proceeds from new term loan			$ 1,500,000,000
Senior Notes [Member] | Senior Secured Notes Due 2027 [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 1,200,000,000
Debt instrument, stated interest		4.50%
Senior Notes [Member] | Senior Secured Notes Due 2024 [Member]
Debt Instrument [Line Items]
Proceeds from new term loan		$ 1,200,000,000
Senior Notes [Member] | Senior Secured Notes Due 2047 [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 1,500,000,000
Debt instrument, stated interest	5.50%
Senior Notes [Member] | Senior Secured Notes Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, stated interest	8.00%
Proceeds from new term loan	$ 500,000,000

XML

Capital Structure - Schedule of Changes in Stockholders' Deficit and Equity (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Capital Structure [Line Items]
Beginning Balances			$ (5,633)
Comprehensive income	$ 822	$ 741	1,617	$ 1,523
Repurchase of common stock			(966)
Distributions			(248)
Share-based benefit plans			117
Other			34
Ending Balances	(5,079)		(5,079)
Common Stock [Member]
Capital Structure [Line Items]
Beginning Balances			4
Ending Balances	$ 4		$ 4
Beginning Balances, Shares			370,536,000
Repurchase of common stock, shares			(11,525,000)
Share-based benefit plans, Shares			3,884,000
Ending Balances, Shares	362,895,000		362,895,000
Capital in Excess of Par Value [Member]
Capital Structure [Line Items]
Repurchase of common stock			$ (115)
Share-based benefit plans			117
Other			(2)
Accumulated Other Comprehensive Loss [Member]
Capital Structure [Line Items]
Beginning Balances			(338)
Comprehensive income			45
Ending Balances	$ (293)		(293)
Retained Deficit [Member]
Capital Structure [Line Items]
Beginning Balances			(6,968)
Comprehensive income			1,316
Repurchase of common stock			(851)
Ending Balances	(6,503)		(6,503)
Equity Attributable to Noncontrolling Interests [Member]
Capital Structure [Line Items]
Beginning Balances			1,669
Comprehensive income			256
Distributions			(248)
Other			36
Ending Balances	$ 1,713		$ 1,713

XML

Capital Structure - Additional Information (Detail) - Common Stock [Member] - USD ($)	6 Months Ended
	Jun. 30, 2017	Nov. 30, 2016
Capital Structure [Line Items]
Repurchase of common stock, shares	(11,525,000)
Repurchase price of common stock, per share	$ 83.81
Share repurchase program, remaining authorized repurchase amount	$ 887,000,000
Share repurchase program authorized amount		$ 2,000,000,000

XML

Capital Structure - Components of Accumulated Other Comprehensive Loss (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2017 USD ($)
Equity [Abstract]
Unrealized gains on available-for-sale securities, beginning balances	$ 7
Unrealized gains on available-for-sale securities, net of income taxes	3
Unrealized gains on available-for-sale securities, ending balances	10
Foreign currency translation adjustments, beginning balances	(211)
Foreign currency translation adjustments	33
Foreign currency translation adjustments, ending balances	(178)
Defined benefit plans, beginning balances	(146)
Defined benefit plans, (income) expense reclassified into operations from other comprehensive income	6
Defined benefit plans, ending balances	(140)
Change in fair value of derivative instruments, beginning balances	12
Change in fair value of derivative instruments net of income taxes	(5)
Change in fair value of derivatives instruments, (income) expense reclassified into operations from other comprehensive income	8
Change in fair value of derivative instruments, ending balances	15
Accumulated other comprehensive income, net of tax, beginning balances	(338)
Unrealized gains on available-for-sale securities, net of income taxes	3
Foreign currency translation adjustments	33
Change in fair value of derivative instruments	(5)
Expense reclassified into operations from other comprehensive income, Total	14
Accumulated other comprehensive income (loss), net of tax, ending balances	$ (293)

XML

Capital Structure - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2017 USD ($)
Equity [Abstract]
Unrealized gains on available-for-sale securities, tax portion	$ 2
Foreign currency translation adjustments, income taxes	22
Defined benefit plans, Expense reclassified into operations from other comprehensive income, Income tax benefits	3
Change in fair value of derivative instruments, change in fair value of derivative instruments, income taxes	3
Change in fair value of derivative instruments, Expense reclassified into operations from other comprehensive income, income tax benefits	$ 5

XML

Segment and Geographic Information - Additional Information (Detail) - Hospital	3 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Number of geographically organized groups	2
Number of owned and operated hospitals	172
Reorganization Group [Member] | National Group [Member]
Segment Reporting Information [Line Items]
Number of owned and operated hospitals		86
Reorganization Group [Member] | American Group [Member]
Segment Reporting Information [Line Items]
Number of owned and operated hospitals		80
Reorganization Group [Member] | Corporate and Other [Member]
Segment Reporting Information [Line Items]
Number of owned and operated hospitals		6

XML

Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Revenues	$ 10,733	$ 10,319	$ 21,356	$ 20,579
Equity in earnings of affiliates	13	10	23	22
Adjusted segment EBITDA	2,090	2,052	4,095	4,055
Depreciation and amortization	521	489	1,042	968
Interest expense	411	427	830	843
Gains on sales of facilities	(2)	(6)	(3)	(5)
Legal claim costs		10		22
Income before income taxes	1,160	1,132	2,226	2,227
National Group [Member]
Segment Reporting Information [Line Items]
Revenues	5,160	4,931	10,308	9,898
Equity in earnings of affiliates	(4)	(2)	(9)	(4)
Adjusted segment EBITDA	1,162	1,131	2,293	2,269
Depreciation and amortization	217	201	431	398
American Group [Member]
Segment Reporting Information [Line Items]
Revenues	5,093	4,860	10,088	9,646
Equity in earnings of affiliates	(10)	(8)	(18)	(17)
Adjusted segment EBITDA	1,040	1,004	2,047	1,986
Depreciation and amortization	238	225	476	444
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Revenues	480	528	960	1,035
Equity in earnings of affiliates	1		4	(1)
Adjusted segment EBITDA	(112)	(83)	(245)	(200)
Depreciation and amortization	$ 66	$ 63	$ 135	$ 126

XML

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Additional Information (Detail) - USD ($)	Jun. 30, 2017	Dec. 31, 2012
Supplemental Condensed Consolidating Financial Information [Line Items]
Ownership percentage held by parent	100.00%
Senior Unsecured Notes Due 2021 [Member]
Supplemental Condensed Consolidating Financial Information [Line Items]
Debt instrument, principal amount		$ 1,000,000,000
Debt instrument, stated interest		6.25%

XML

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Schedule of Condensed Consolidating Comprehensive Income Statement (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Condensed Statement of Income Captions [Line Items]
Revenues before provision for doubtful accounts	$ 11,806	$ 11,081	$ 23,189	$ 22,131
Provision for doubtful accounts	1,073	762	1,833	1,552
Revenues	10,733	10,319	21,356	20,579
Salaries and benefits	4,896	4,691	9,797	9,393
Supplies	1,795	1,718	3,592	3,432
Other operating expenses	1,965	1,868	3,895	3,721
Equity in earnings of affiliates	(13)	(10)	(23)	(22)
Depreciation and amortization	521	489	1,042	968
Interest expense	411	427	830	843
Gains on sales of facilities	(2)	(6)	(3)	(5)
Legal claim costs		10		22
Total expenses including equity in earnings of affiliates	9,573	9,187	19,130	18,352
Income (loss) before income taxes	1,160	1,132	2,226	2,227
Provision (benefit) for income taxes	365	341	654	625
Net income (loss)	795	791	1,572	1,602
Net income attributable to noncontrolling interests	138	133	256	250
Net income (loss) attributable to HCA Healthcare, Inc.	657	658	1,316	1,352
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	684	608	1,361	1,273
HCA Healthcare, Inc. Issuer [Member]
Condensed Statement of Income Captions [Line Items]
Other operating expenses	4	2	5	4
Equity in earnings of affiliates	(658)	(641)	(1,266)	(1,270)
Interest expense	16	16	32	32
Total expenses including equity in earnings of affiliates	(638)	(623)	(1,229)	(1,234)
Income (loss) before income taxes	638	623	1,229	1,234
Provision (benefit) for income taxes	(19)	(35)	(87)	(118)
Net income (loss)	657	658	1,316	1,352
Net income (loss) attributable to HCA Healthcare, Inc.	657	658	1,316	1,352
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	684	608	1,361	1,273
HCA Inc. Issuer [Member]
Condensed Statement of Income Captions [Line Items]
Interest expense	755	670	1,488	1,320
Legal claim costs		10		22
Total expenses including equity in earnings of affiliates	755	680	1,488	1,342
Income (loss) before income taxes	(755)	(680)	(1,488)	(1,342)
Provision (benefit) for income taxes	(279)	(251)	(549)	(495)
Net income (loss)	(476)	(429)	(939)	(847)
Net income (loss) attributable to HCA Healthcare, Inc.	(476)	(429)	(939)	(847)
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	(480)	(431)	(936)	(856)
Subsidiary Guarantors [Member]
Condensed Statement of Income Captions [Line Items]
Revenues before provision for doubtful accounts	6,049	5,693	11,902	11,366
Provision for doubtful accounts	593	498	1,012	992
Revenues	5,456	5,195	10,890	10,374
Salaries and benefits	2,437	2,347	4,903	4,701
Supplies	931	886	1,882	1,784
Other operating expenses	951	893	1,878	1,750
Equity in earnings of affiliates	(1)	(1)	(2)	(3)
Depreciation and amortization	248	238	499	465
Interest expense	(291)	(204)	(560)	(411)
Gains on sales of facilities	(1)	(2)	(1)
Management fees	(212)	(235)	(422)	(395)
Total expenses including equity in earnings of affiliates	4,062	3,922	8,177	7,891
Income (loss) before income taxes	1,394	1,273	2,713	2,483
Provision (benefit) for income taxes	505	462	983	900
Net income (loss)	889	811	1,730	1,583
Net income attributable to noncontrolling interests	27	21	50	43
Net income (loss) attributable to HCA Healthcare, Inc.	862	790	1,680	1,540
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	865	794	1,686	1,546
Subsidiary Non-Guarantors [Member]
Condensed Statement of Income Captions [Line Items]
Revenues before provision for doubtful accounts	5,757	5,388	11,287	10,765
Provision for doubtful accounts	480	264	821	560
Revenues	5,277	5,124	10,466	10,205
Salaries and benefits	2,459	2,344	4,894	4,692
Supplies	864	832	1,710	1,648
Other operating expenses	1,010	973	2,012	1,967
Equity in earnings of affiliates	(12)	(9)	(21)	(19)
Depreciation and amortization	273	251	543	503
Interest expense	(69)	(55)	(130)	(98)
Gains on sales of facilities	(1)	(4)	(2)	(5)
Management fees	212	235	422	395
Total expenses including equity in earnings of affiliates	4,736	4,567	9,428	9,083
Income (loss) before income taxes	541	557	1,038	1,122
Provision (benefit) for income taxes	158	165	307	338
Net income (loss)	383	392	731	784
Net income attributable to noncontrolling interests	111	112	206	207
Net income (loss) attributable to HCA Healthcare, Inc.	272	280	525	577
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	300	228	561	501
Eliminations [Member]
Condensed Statement of Income Captions [Line Items]
Equity in earnings of affiliates	658	641	1,266	1,270
Total expenses including equity in earnings of affiliates	658	641	1,266	1,270
Income (loss) before income taxes	(658)	(641)	(1,266)	(1,270)
Net income (loss)	(658)	(641)	(1,266)	(1,270)
Net income (loss) attributable to HCA Healthcare, Inc.	(658)	(641)	(1,266)	(1,270)
Comprehensive income (loss) attributable to HCA Healthcare, Inc.	$ (685)	$ (591)	$ (1,311)	$ (1,191)

XML

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Schedule of Condensed Consolidating Balance Sheet (Detail) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 705	$ 646	$ 691	$ 741
Accounts receivable, net	5,782	5,826
Inventories	1,544	1,503
Other	1,306	1,111
Total current assets	9,337	9,086
Property and equipment, net	16,768	16,352
Investments of insurance subsidiaries	352	336
Investments in and advances to affiliates	197	206
Goodwill and other intangible assets	6,771	6,704
Other	1,141	1,074
Total assets	34,566	33,758
Current liabilities:
Accounts payable	2,245	2,318
Accrued salaries	1,209	1,265
Other accrued expenses	2,104	2,035
Long-term debt due within one year	213	216
Total current liabilities	5,771	5,834
Long-term debt, net	31,448	31,160
Professional liability risks	1,144	1,148
Income taxes and other liabilities	1,282	1,249
Total liabilities	39,645	39,391
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(6,792)	(7,302)
Noncontrolling interests	1,713	1,669
Total stockholders' deficit	(5,079)	(5,633)
Total liabilities and stockholders' deficit	34,566	33,758
HCA Healthcare, Inc. Issuer [Member]
Current assets:
Investments in and advances to affiliates	28,356	27,045
Other	805	877
Total assets	29,161	27,922
Current liabilities:
Other accrued expenses	281	29
Total current liabilities	281	29
Long-term debt, net	994	993
Intercompany balances	34,258	33,784
Income taxes and other liabilities	420	418
Total liabilities	35,953	35,224
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(6,792)	(7,302)
Total stockholders' deficit	(6,792)	(7,302)
Total liabilities and stockholders' deficit	29,161	27,922
HCA Inc. Issuer [Member]
Current assets:
Other	29
Total assets	29
Current liabilities:
Other accrued expenses	383	572
Long-term debt due within one year	97	97
Total current liabilities	480	669
Long-term debt, net	29,981	29,693
Intercompany balances	(9,404)	(10,277)
Income taxes and other liabilities	5	12
Total liabilities	21,062	20,097
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(21,033)	(20,097)
Total stockholders' deficit	(21,033)	(20,097)
Total liabilities and stockholders' deficit	29
Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	155	110	82	155
Accounts receivable, net	2,991	3,028
Inventories	923	890
Other	522	445
Total current assets	4,591	4,473
Property and equipment, net	8,560	8,463
Investments in and advances to affiliates	15	16
Goodwill and other intangible assets	1,727	1,728
Other	33	34
Total assets	14,926	14,714
Current liabilities:
Accounts payable	1,342	1,439
Accrued salaries	679	704
Other accrued expenses	457	464
Long-term debt due within one year	57	60
Total current liabilities	2,535	2,667
Long-term debt, net	188	199
Intercompany balances	(27,765)	(26,447)
Income taxes and other liabilities	403	387
Total liabilities	(24,639)	(23,194)
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	39,438	37,752
Noncontrolling interests	127	156
Total stockholders' deficit	39,565	37,908
Total liabilities and stockholders' deficit	14,926	14,714
Subsidiary Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	550	536	$ 609	$ 586
Accounts receivable, net	2,791	2,798
Inventories	621	613
Other	784	666
Total current assets	4,746	4,613
Property and equipment, net	8,208	7,889
Investments of insurance subsidiaries	352	336
Investments in and advances to affiliates	182	190
Goodwill and other intangible assets	5,044	4,976
Other	274	163
Total assets	18,806	18,167
Current liabilities:
Accounts payable	903	879
Accrued salaries	530	561
Other accrued expenses	983	970
Long-term debt due within one year	59	59
Total current liabilities	2,475	2,469
Long-term debt, net	285	275
Intercompany balances	2,911	2,940
Professional liability risks	1,144	1,148
Income taxes and other liabilities	454	432
Total liabilities	7,269	7,264
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	9,951	9,390
Noncontrolling interests	1,586	1,513
Total stockholders' deficit	11,537	10,903
Total liabilities and stockholders' deficit	18,806	18,167
Eliminations [Member]
Current assets:
Investments in and advances to affiliates	(28,356)	(27,045)
Total assets	(28,356)	(27,045)
Current liabilities:
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(28,356)	(27,045)
Total stockholders' deficit	(28,356)	(27,045)
Total liabilities and stockholders' deficit	$ (28,356)	$ (27,045)

XML

Supplemental Condensed Consolidating Financial Information and Other Collateral-Related Information - Schedule of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ 795	$ 791	$ 1,572	$ 1,602
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities			(2,228)	(1,642)
Provision for doubtful accounts	1,073	762	1,833	1,552
Depreciation and amortization	521	489	1,042	968
Income taxes			267	67
Gains on sales of facilities	(2)	(6)	(3)	(5)
Legal claim costs		10		22
Amortization of debt issuance costs			16	18
Share-based compensation			140	129
Other			45	37
Net cash provided by (used in) operating activities			2,684	2,748
Cash flows from investing activities:
Purchase of property and equipment			(1,304)	(1,172)
Acquisition of hospitals and health care entities			(295)	(430)
Disposition of hospitals and health care entities			14	14
Change in investments			(11)	18
Other			5	15
Net cash used in investing activities			(1,591)	(1,555)
Cash flows from financing activities:
Issuance of long-term debt			1,502	3,000
Net change in revolving credit facilities			(1,160)
Repayment of long-term debt			(95)	(2,065)
Distributions to noncontrolling interests			(248)	(205)
Payment of debt issuance costs			(25)	(24)
Repurchases of common stock			(966)	(1,858)
Other			(42)	(91)
Net cash (used in) provided by financing activities			(1,034)	(1,243)
Change in cash and cash equivalents			59	(50)
Cash and cash equivalents at beginning of period			646	741
Cash and cash equivalents at end of period	705	691	705	691
Eliminations [Member]
Cash flows from operating activities:
Net income (loss)	(658)	(641)	(1,266)	(1,270)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of affiliates			1,266	1,270
HCA Healthcare, Inc. Issuer [Member]
Cash flows from operating activities:
Net income (loss)	657	658	1,316	1,352
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities			1	(23)
Income taxes			267	67
Equity in earnings of affiliates			(1,266)	(1,270)
Other			39	37
Net cash provided by (used in) operating activities			357	163
Cash flows from financing activities:
Repurchases of common stock			(966)	(1,858)
Changes in intercompany balances with affiliates, net			671	1,799
Other			(62)	(104)
Net cash (used in) provided by financing activities			(357)	(163)
HCA Inc. Issuer [Member]
Cash flows from operating activities:
Net income (loss)	(476)	(429)	(939)	(847)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities			(189)	66
Legal claim costs		10		22
Amortization of debt issuance costs			16	18
Net cash provided by (used in) operating activities			(1,112)	(741)
Cash flows from financing activities:
Issuance of long-term debt			1,500	3,000
Net change in revolving credit facilities			(1,160)
Repayment of long-term debt			(42)	(2,005)
Payment of debt issuance costs			(25)	(24)
Changes in intercompany balances with affiliates, net			839	(230)
Net cash (used in) provided by financing activities			1,112	741
Subsidiary Guarantors [Member]
Cash flows from operating activities:
Net income (loss)	889	811	1,730	1,583
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities			(1,189)	(1,140)
Provision for doubtful accounts	593	498	1,012	992
Depreciation and amortization	248	238	499	465
Gains on sales of facilities	(1)	(2)	(1)
Share-based compensation			140	129
Other				(2)
Net cash provided by (used in) operating activities			2,191	2,027
Cash flows from investing activities:
Purchase of property and equipment			(578)	(482)
Acquisition of hospitals and health care entities			(5)	(148)
Disposition of hospitals and health care entities			10	9
Change in investments				3
Other			2	(1)
Net cash used in investing activities			(571)	(619)
Cash flows from financing activities:
Repayment of long-term debt			(33)	(38)
Distributions to noncontrolling interests			(79)	(29)
Changes in intercompany balances with affiliates, net			(1,463)	(1,414)
Net cash (used in) provided by financing activities			(1,575)	(1,481)
Change in cash and cash equivalents			45	(73)
Cash and cash equivalents at beginning of period			110	155
Cash and cash equivalents at end of period	155	82	155	82
Subsidiary Non-Guarantors [Member]
Cash flows from operating activities:
Net income (loss)	383	392	731	784
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Changes in operating assets and liabilities			(851)	(545)
Provision for doubtful accounts	480	264	821	560
Depreciation and amortization	273	251	543	503
Gains on sales of facilities	(1)	(4)	(2)	(5)
Other			6	2
Net cash provided by (used in) operating activities			1,248	1,299
Cash flows from investing activities:
Purchase of property and equipment			(726)	(690)
Acquisition of hospitals and health care entities			(290)	(282)
Disposition of hospitals and health care entities			4	5
Change in investments			(11)	15
Other			3	16
Net cash used in investing activities			(1,020)	(936)
Cash flows from financing activities:
Issuance of long-term debt			2
Repayment of long-term debt			(20)	(22)
Distributions to noncontrolling interests			(169)	(176)
Changes in intercompany balances with affiliates, net			(47)	(155)
Other			20	13
Net cash (used in) provided by financing activities			(214)	(340)
Change in cash and cash equivalents			14	23
Cash and cash equivalents at beginning of period			536	586
Cash and cash equivalents at end of period	$ 550	$ 609	$ 550	$ 609